CN102746292A - Cyclized berberine derivatives, preparation method and uses thereof - Google Patents
Cyclized berberine derivatives, preparation method and uses thereof Download PDFInfo
- Publication number
- CN102746292A CN102746292A CN201210101607XA CN201210101607A CN102746292A CN 102746292 A CN102746292 A CN 102746292A CN 201210101607X A CN201210101607X A CN 201210101607XA CN 201210101607 A CN201210101607 A CN 201210101607A CN 102746292 A CN102746292 A CN 102746292A
- Authority
- CN
- China
- Prior art keywords
- dioxole
- dihydro
- phenanthridines
- cde
- isoquino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 150000003832 berberine derivatives Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 100
- -1 nitro, cyano, amino, hydroxy Chemical group 0.000 claims abstract description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 14
- 150000002367 halogens Chemical group 0.000 claims abstract description 14
- 239000001257 hydrogen Substances 0.000 claims abstract description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 11
- 239000012453 solvate Substances 0.000 claims abstract description 11
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims description 70
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 claims description 50
- 239000002904 solvent Substances 0.000 claims description 38
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 33
- 229940093265 berberine Drugs 0.000 claims description 31
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 30
- 150000001263 acyl chlorides Chemical class 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 239000002253 acid Substances 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000002585 base Substances 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 239000003981 vehicle Substances 0.000 claims description 9
- 239000003513 alkali Substances 0.000 claims description 7
- FZAGOOYMTPGPGF-UHFFFAOYSA-N Lambertine Chemical compound C1=C2C3=CC4=CC=C(OC)C(OC)=C4CN3CCC2=CC2=C1OCO2 FZAGOOYMTPGPGF-UHFFFAOYSA-N 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- IBGCXOFOCKCBNQ-UHFFFAOYSA-N nitro cyanate Chemical compound [O-][N+](=O)OC#N IBGCXOFOCKCBNQ-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000006332 fluoro benzoyl group Chemical group 0.000 claims description 4
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011630 iodine Chemical group 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- GLGSZERYOLHNML-UHFFFAOYSA-N $l^{1}-oxidanyl(phenyl)methanone Chemical compound [O]C(=O)C1=CC=CC=C1 GLGSZERYOLHNML-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- MVPPADPHJFYWMZ-IDEBNGHGSA-N chlorobenzene Chemical group Cl[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 MVPPADPHJFYWMZ-IDEBNGHGSA-N 0.000 claims description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Substances ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 229940015043 glyoxal Drugs 0.000 claims description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000005257 alkyl acyl group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 144
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 132
- 238000010992 reflux Methods 0.000 description 104
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 92
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 84
- 239000007787 solid Substances 0.000 description 64
- 239000000047 product Substances 0.000 description 55
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- 238000000926 separation method Methods 0.000 description 50
- 238000000967 suction filtration Methods 0.000 description 50
- 229960001866 silicon dioxide Drugs 0.000 description 49
- 230000006837 decompression Effects 0.000 description 48
- 238000000746 purification Methods 0.000 description 48
- 239000000741 silica gel Substances 0.000 description 48
- 229910002027 silica gel Inorganic materials 0.000 description 48
- 125000001309 chloro group Chemical group Cl* 0.000 description 46
- 238000012544 monitoring process Methods 0.000 description 42
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 42
- 238000001816 cooling Methods 0.000 description 40
- 238000010792 warming Methods 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 28
- 238000004821 distillation Methods 0.000 description 23
- 239000000463 material Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000004567 concrete Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- 102000003915 DNA Topoisomerases Human genes 0.000 description 5
- 108090000323 DNA Topoisomerases Proteins 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 235000011194 food seasoning agent Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- PAEZRCINULFAGO-OAQYLSRUSA-N (R)-homocamptothecin Chemical compound CC[C@@]1(O)CC(=O)OCC(C2=O)=C1C=C1N2CC2=CC3=CC=CC=C3N=C21 PAEZRCINULFAGO-OAQYLSRUSA-N 0.000 description 3
- RLQYRXCUPVKSAW-UHFFFAOYSA-M 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;chloride Chemical compound [Cl-].COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=C1 RLQYRXCUPVKSAW-UHFFFAOYSA-M 0.000 description 3
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- RIDQRIPSFYHEGL-UHFFFAOYSA-N fibrauretin Natural products CC12CC=C3C(=O)OC(CC3(C)C1C(=O)C=CC2=O)c4cocc4 RIDQRIPSFYHEGL-UHFFFAOYSA-N 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000000452 restraining effect Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- XHQZJYCNDZAGLW-UHFFFAOYSA-N 3-methoxybenzoic acid Chemical compound COC1=CC=CC(C(O)=O)=C1 XHQZJYCNDZAGLW-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ZRBGFWOXAQPDTH-UHFFFAOYSA-N umbellatine Natural products C1=C2C3=CC4=CC=C(OC)C(OC)=C4C(O)N3CCC2=CC2=C1OCO2 ZRBGFWOXAQPDTH-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- RHBGITBPARBDPH-ZPUQHVIOSA-N (E,E)-piperic acid Chemical compound OC(=O)\C=C\C=C\C1=CC=C2OCOC2=C1 RHBGITBPARBDPH-ZPUQHVIOSA-N 0.000 description 1
- 0 *Oc(cc(CC1)c2c3*1cc(c(O*)c(cc1)OC=I)c1c3ccc21)c1O* Chemical compound *Oc(cc(CC1)c2c3*1cc(c(O*)c(cc1)OC=I)c1c3ccc21)c1O* 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- QSSXJPIWXQTSIX-UHFFFAOYSA-N 1-bromo-2-methylbenzene Chemical compound CC1=CC=CC=C1Br QSSXJPIWXQTSIX-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UVFWYVCDRKRAJH-UHFFFAOYSA-N 2-bromo-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1Br UVFWYVCDRKRAJH-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- ICXSHFWYCHJILC-UHFFFAOYSA-N 2-fluoro-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1F ICXSHFWYCHJILC-UHFFFAOYSA-N 0.000 description 1
- GPZXFICWCMCQPF-UHFFFAOYSA-N 2-methylbenzoyl chloride Chemical compound CC1=CC=CC=C1C(Cl)=O GPZXFICWCMCQPF-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- MXNBDFWNYRNIBH-UHFFFAOYSA-N 3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1 MXNBDFWNYRNIBH-UHFFFAOYSA-N 0.000 description 1
- AFPHTEQTJZKQAQ-UHFFFAOYSA-N 3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- GRDXCFKBQWDAJH-UHFFFAOYSA-N 4-acetamidobenzenesulfonyl chloride Chemical compound CC(=O)NC1=CC=C(S(Cl)(=O)=O)C=C1 GRDXCFKBQWDAJH-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- BOJWTAQWPVBIPG-UHFFFAOYSA-N 4-fluoro-3-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C([N+]([O-])=O)=C1 BOJWTAQWPVBIPG-UHFFFAOYSA-N 0.000 description 1
- BBEWSMNRCUXQRF-UHFFFAOYSA-N 4-methyl-3-nitrobenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1[N+]([O-])=O BBEWSMNRCUXQRF-UHFFFAOYSA-N 0.000 description 1
- RYAQFHLUEMJOMF-UHFFFAOYSA-N 4-phenoxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OC1=CC=CC=C1 RYAQFHLUEMJOMF-UHFFFAOYSA-N 0.000 description 1
- IODMEDPPCXSFLD-UHFFFAOYSA-N 5-nitrofuran-2-carboxylic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)O1 IODMEDPPCXSFLD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- DFXQXFGFOLXAPO-UHFFFAOYSA-N 96-99-1 Chemical compound OC(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 DFXQXFGFOLXAPO-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 1
- LEZUBHVVTQZWET-UHFFFAOYSA-N C(=O)Cl.FC1=CC=CC(=C1)F Chemical compound C(=O)Cl.FC1=CC=CC(=C1)F LEZUBHVVTQZWET-UHFFFAOYSA-N 0.000 description 1
- 101100190268 Caenorhabditis elegans pah-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001215120 Leptospirales Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical compound COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 201000002014 Suppurative Otitis Media Diseases 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- MXMOTZIXVICDSD-UHFFFAOYSA-N anisoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1 MXMOTZIXVICDSD-UHFFFAOYSA-N 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 150000003818 basic metals Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229950005953 camsilate Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- XAEXSWVTEJHRMH-UHFFFAOYSA-N chloropyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)S1 XAEXSWVTEJHRMH-UHFFFAOYSA-N 0.000 description 1
- 229950005434 chloropyrilene Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-O ethylaminium Chemical compound CC[NH3+] QUSNBJAOOMFDIB-UHFFFAOYSA-O 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000451 gelidium spp. gum Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-M glutaminate Chemical compound [O-]C(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-M 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000001457 metallic cations Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 150000003810 morphinanes Chemical class 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- NTQYXUJLILNTFH-UHFFFAOYSA-N nonanoyl chloride Chemical compound CCCCCCCCC(Cl)=O NTQYXUJLILNTFH-UHFFFAOYSA-N 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- XCXHVVWAGKXDTH-UHFFFAOYSA-N pyridin-1-ium;iodate Chemical compound [O-]I(=O)=O.C1=CC=[NH+]C=C1 XCXHVVWAGKXDTH-UHFFFAOYSA-N 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960000658 sumatriptan succinate Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to cyclized berberine derivatives, a preparation method and uses thereof. The present invention specifically relates to compounds represented by a formula I or a pharmaceutically-acceptable salt or a solvate thereof, wherein X is a halogen, R is selected from hydrogen, C1-6 alkyl, phenyl substituted C1-6 alkyl, C1-18 alkylacyl, benzoyl, benzenesulfonyl, and 3,4-C1-3alkylidene dioxybenzoyl, the phenyl is optionally substituted by 1-4 substituents selected from halogen, C1-6 alkyl, C1-6 alkoxy, nitro, cyano, amino, hydroxy, C1-4 alkyl acylamino. The compounds of the present invention have beneficial physiological activities.
Description
Technical field
The invention belongs to the medical chemistry field; Be specifically related to one type of new compound that can be used as antineoplastic agent; Be particularly related to one type and have cyclisation berberinc derivate of anti-tumor activity and preparation method thereof, and this compounds as medicine particularly as the for example application aspect the medicine of anti-liver neoplasm of antitumor drug.
Background technology
Tumour and cancer are one of healthy major diseases of harm humans.Tumour be body under various carcinogenic factor effects, some cells of local organization lose the normal regulation to its growth on gene level, cause its clonal abnormality hyperplasia and the true tumor that forms.It is generally acknowledged that tumour cell is a monoclonicity, promptly all oncocytes in tumour all are offsprings of the cell of a sudden change.Generally tumour is divided into optimum and pernicious two big types.All malignant tumours are generically and collectively referred to as cancer.The physician points out that cancer is because of being: body in environmental pollution, chemical pollution (chemical toxicant), ionizing rays, radical toxin, mikrobe (bacterium, fungi, virus etc.) and metabolism toxin, hereditary property, internal secretion is unbalance, cause the result of health normal cell generation canceration under the effect of the various carcinogenic substances of immunologic function disorder or the like, carcinogenic factor, often show as: the cellular abnormality hyperplasia of local organization and the local lump that forms.Cancer is that organism normal cell is in many reasons, multistage and the caused one big type of disease of repeatedly suddenling change.
Know that (Berberine BBR), is called Umbellatine again to Berberine, is a kind of common morphinane alkaloid, and its molecular formula is [C
20H
18NO
4]
+It is present in many plants of ten genus of four sections such as Berberidaceae, and M.-E. Xia Waliai in 1826 and G. Pei Ertan obtain from the Xanthoxylonclava bark first first.Berberine is a kind of quartermary ammonium alkaloids, from ether, can separate out yellow needle-like crystal; 145 ℃ of fusing points; Water-soluble, be insoluble in benzene, EC.The solubleness of its esters in water is all smaller, and for example hydrochloride is 1: 500, and vitriol is 1: 30.Berberine has restraining effect to dysentery bacterium, intestinal bacteria, pneumococcus, golden Portugal bacterium, suis, Corynebacterium diphtheriae and ameba.Clinical berberine hydrochloride commonly used is its 2 hydrate, is mainly used in intestinal tract infections and bacillary dysentery etc.Recently find also that Berberine has antiarrhythmic effect and can be used to treat mellitus.The has a broad antifungal spectrum of Berberine, external to multiple gram-positive and the equal tool bacteriostatic action of negative bacterium, wherein to Hemolytic streptococcus, golden Portugal bacterium, vibrio cholerae.Meningococcus, shigella, Corynebacterium diphtheriae, diphtheria corynebacterium etc. have stronger restraining effect, and be antibacterial during lower concentration, sterilization during high density.Influenza virus, ameba, leptospiral, some dermatophytes also there is certain restraining effect.Experiment in vitro confirms that Umbellatine can strengthen the phagocytic activity of white corpuscle and liver reticuloendothelial system.Dysentery bacterium, Hemolytic streptococcus, golden Portugal bacterium etc. very easily produce resistance to these article.Berberine and penicillium mould, Streptomycin sulphate etc. do not have cross resistance.Berberine is mainly used in intestinal tract infectionss such as treatment gastro-enteritis, bacillary dysentery clinically at present, and is effective for eye conjunctivitis, suppurative otitis media etc.
People still expect novelty is arranged and the effective antitumour medicine for example the medicine of anti-liver neoplasm be used for clinical.
Summary of the invention
The objective of the invention is to seek and have the for example new compound of anti-liver neoplasm of effective antitumour.The wonderful discovery of the inventor, the cyclisation berberinc derivate with formula I structure has wonderful effect.The present invention is based on this discovery and be accomplished.
For this reason, first aspect present invention provides with the following formula I compound:
Or its pharmacologically acceptable salts or solvate, wherein
X is a halogen;
R
1Be selected from: hydrogen, C
1-6Alkyl, the substituted C of phenyl
1-6Alkyl, C
1-18Alkyl acyl, benzoyl-, benzenesulfonyl, 3,4-C
1-3The alkylenedioxy group benzoyl-, wherein said phenyl is optional to be selected from following substituting group replacement by 1 to 4: halogen, C
1-6Alkyl, C
1-6Alkoxyl group, nitro, cyanic acid, amino, hydroxyl, C
1-4Alkyl acyl is amino;
R
2And R
3Be selected from independently of one another: hydrogen, C
1-6Alkyl, benzoyl-, wherein said phenyl is optional to be replaced by 1 to 4 halogen; Perhaps R
2And R
3Be together-CH
2-(be R
2And R
3The Sauerstoffatom that connects with their forms the ring of a dioxole).
According to the compound of first aspect present invention, wherein R
2And R
3Be selected from independently of one another: hydrogen, C
1-4Alkyl, halogeno-benzene formyl radical; Perhaps R
2And R
3Be together-CH
2-(be R
2And R
3The Sauerstoffatom that connects with their forms the ring of a dioxole).
According to the compound of first aspect present invention, it is the compound with Formula Il:
Or its pharmacologically acceptable salts or solvate, wherein
X is a halogen;
R is selected from: hydrogen, C
1-6Alkyl, the substituted C of phenyl
1-6Alkyl, C
1-18Alkyl acyl, benzoyl-, benzenesulfonyl, 3,4-C
1-3The alkylenedioxy group benzoyl-, wherein said phenyl is optional to be selected from following substituting group replacement by 1 to 4: halogen, C
1-6Alkyl, C
1-6Alkoxyl group, nitro, cyanic acid, amino, hydroxyl, C
1-4Alkyl acyl is amino.
According to the compound of first aspect present invention, wherein X is selected from fluorine, chlorine, bromine, iodine.In one embodiment, X is selected from chlorine, bromine, iodine.
According to the compound of first aspect present invention, wherein R is selected from hydrogen, C
1-4Alkyl, the substituted C of phenyl
1-4Alkyl, C
1-16Alkyl acyl, benzoyl-, benzenesulfonyl, 3,4-C
1-2The alkylenedioxy group benzoyl-, wherein said phenyl is optional to be selected from following substituting group replacement by 1 to 4: halogen, C
1-4Alkyl, C
1-4Alkoxyl group, nitro, cyanic acid, amino, hydroxyl, C
1-4Alkyl acyl is amino.
According to the compound of first aspect present invention, wherein R is selected from hydrogen, C
1-4Alkyl, the substituted C of phenyl
1-4Alkyl, C
1-16Alkyl acyl, benzoyl-, benzenesulfonyl, 3,4-methylene-dioxy benzoyl-, wherein said phenyl is optional to be selected from following substituting group replacement by 1 to 4: halogen, C
1-4Alkyl, C
1-4Alkoxyl group, nitro, cyanic acid, amino, hydroxyl, C
1-4Alkyl acyl is amino.
According to the compound of first aspect present invention, it is a following formula: compound,
R wherein
1, R
2, R
3Have each said implication of following numbering (No1 to No51) with X:
According to the compound of first aspect present invention, it is to be selected from following compound:
9,10-dimethoxy-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-hydroxyl-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-oxyethyl group-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-bromide;
9-butoxy-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-iodide;
9-benzyloxy-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-bromide;
9-(2,4 difluorobenzene base) methoxyl group-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-bromide;
9-ethanoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-benzoyl-Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to methyl benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to anisoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to fluoro benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to fluorine m-nitro benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to methyl m-nitro benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to methoxyl group m-nitro benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-(3,4-methylene-dioxy benzoyl-oxygen base)-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-(3,4,5-trimethoxy benzoyl-oxygen base)-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
The adjacent fluoro benzoyl Oxy-1 of 9-0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
The adjacent chlorobenzene formacyl Oxy-1 of 9-0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-(2,4 difluorobenzene formyl radical oxygen base)-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to acetamido benzenesulfonyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-benzenesulfonyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-decanoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-lauroyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-hexadecanoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
Or its pharmacologically acceptable salts or solvate.
According to the compound of first aspect present invention, it is like the embodiment of the invention prepared compound or its pharmacologically acceptable salts or solvate.
Second aspect present invention provides the method for preparing each said formula I compound of first aspect present invention, and it may further comprise the steps:
A) in solvent (for example methyl alcohol), in the presence of alkali (for example salt of wormwood, sodium hydroxide etc. or its combination), make the reaction of Peng Qinghuana and Berberine, obtain dihydroberberine;
B) in solvent (for example acetonitrile), exist down in acid (for example organic acid, for example acetate), make dihydroberberine and glyoxal reaction, obtain the cyclisation Berberine shown in the formula Ia:
Choose wantonly, formula Ia cyclisation Berberine handled down under vacuum (for example 10-60mmHg, for example 20-40mmHg), at high temperature (for example 150～250 ℃, for example 180～230 ℃) obtained the 9-hydroxyl cyclisation Berberine shown in the formula Ib:
Choose wantonly; D) in organic solvent (for example DMF); In the presence of alkali (for example sodium hydroxide, Pottasium Hydroxide), make 9-hydroxyl cyclisation Berberine and suitable reagent (for example halohydrocarbon, for example halogenated alkane, the substituted halogenated alkane of the phenyl) reaction of formula Ib; Obtain 9-alkyl oxy cyclisation Berberine, alkyl wherein is optional to be replaced by phenyl or substituted phenyl;
Choose wantonly; E) in organic solvent (for example acetonitrile); In the presence of reagent (for example pyridine); Make 9-hydroxyl cyclisation Berberine and acyl chlorides or the SULPHURYL CHLORIDE reaction of formula Ib, obtain 9-acyloxy cyclisation Berberine or 9-alkylsulfonyl oxygen basic ring Berberine, acyl group wherein is alkyloyl or benzoyl-.
In the preparation method of second aspect present invention, under necessary situation, in formula I compound process; For preventing that some group (like amino, hydroxyl etc.) from undesirable reaction taking place; Need protect these groups, simultaneously, remove the protection base in due course.These embodiment are too numerous to enumerate, and the use of the protection base of specifically not mentioning and the method for deprotection also belong within the scope of the present invention.
Third aspect present invention relates to a kind of pharmaceutical composition, and it comprises each described formula I compound of first aspect present invention, and optional one or more pharmaceutically acceptable carriers or vehicle.
Fourth aspect present invention relates to each described formula I compound of first aspect present invention is used for treating and/or preventing the medicine of Mammals (comprising the people) tumour or cancer property disease (for example liver cancer) in preparation purposes.
Fifth aspect present invention relates to a kind of method that in the Mammals of needs is arranged, treats and/or prevents Mammals (comprising the people) tumour or cancer property disease (for example liver cancer), and this method comprises each the described formula I compound of first aspect present invention to the administration treatment significant quantity that needs are arranged.
Sixth aspect present invention relates to the pharmaceutical composition that is used to treat and/or prevent Mammals (comprising the people) tumour or cancer property disease (for example liver cancer); This pharmaceutical composition comprises each described formula I compound of first aspect present invention, and optional one or more pharmaceutically acceptable carriers or vehicle.
Seventh aspect present invention also relates to each the described formula I compound of first aspect present invention that is used to treat and/or prevent Mammals (comprising the people) tumour or cancer property disease (for example liver cancer).
Arbitrary embodiment of arbitrary aspect of the present invention can make up with other embodiment, as long as they contradiction can not occur.In addition, in the arbitrary embodiment aspect the present invention is arbitrary, arbitrary technical characterictic goes for this technical characterictic in other embodiment, as long as they contradiction can not occur.
Do further description in the face of the present invention down.
All documents that the present invention quoted from, their full content is incorporated this paper by reference into, and if the expressed implication of these documents and the present invention when inconsistent, be as the criterion with statement of the present invention.In addition; Various terms and phrase that the present invention uses have the general sense of well known to a person skilled in the art; Nonetheless; The present invention still hopes at this more detailed explanation and explanation to be done in these terms and phrase, and term of mentioning and phrase are as the criterion with the implication that the present invention was explained if any inconsistent with known implication.
Those skilled in the art know, and the main ring of Berberine and annular atoms can be by following exemplary serial numbers:
Similarly, for formula I compound of the present invention, for example for for formula Ia compound of the present invention, wherein corresponding five rings and the numbering of part annular atoms are can example following:
Therefore in the present invention, when mentioning " cyclisation Berberine ", be meant berberinc derivate with following formula Ia.Further, when mentioning " 9-hydroxyl cyclisation Berberine ", be meant with the berberinc derivate shown in the following formula Ib:
Again for example, when mentioning " 9-oxyethyl group cyclisation Berberine ", be meant that the 9-position is the The compounds of this invention of oxyethyl group.
In the present invention, term " halogen " or " halo " are meant fluorine, chlorine, bromine and iodine.In the present invention, and group " 3,4-C
1-3The alkylenedioxy group benzoyl-" in group part " C
1-3Alkylidene group " be meant alkylidene group with 1 to 3 carbon atom.
Among the present invention, when mentioning, the term that is adopted " alkyl " comprises alkyl, thiazolinyl and alkynyl, and cyclic group, for example the group of aromatic ring (like phenyl ring) or non-aromatic ring (for example cyclohexane ring).In the present invention, mention C
1-6During alkyl, it comprises its any subset, for example comprises C
1-5Alkyl, C
1-4Alkyl, C
1-3Alkyl, and methyl, ethyl, n-propyl, sec.-propyl, normal-butyl etc.
In the method for synthetic compound of formula i of the present invention, the various starting material that react used are that those skilled in the art can prepare according to existing knowledge, or can make through the document known method, or can buy through commerce.Used midbody, starting material, reagent, reaction conditions etc. all can be made appropriate change according to those skilled in the art existing knowledge in the above reaction scheme.Perhaps, those skilled in the art also can synthesize other formula I compound that the present invention does not specifically enumerate according to the second aspect present invention method.
Formula I compound of the present invention can use with other activeconstituents combination, as long as it does not produce other detrimental actions, for example anaphylaxis.
Active compound shown in the formula I of the present invention can be used as unique antitumor/cancer therapy drug and uses, and perhaps can unite use with one or more other antibacterials.Combination therapy realizes through each being treated component while, order or separating administration.
Term used herein " compsn " means and comprises the product of respectively specifying composition that comprises specified amount, and directly or indirectly from any product of the combination results of respectively specifying composition of specified amount.In the present invention, term " compsn " can exchange with " pharmaceutical composition " and use.
Compound of the present invention can use with the form derived from mineral acid or organic acid pharmacologically acceptable salts.Word " pharmacologically acceptable salts " refers in reliable medical judgment scope, be suitable for contacting with zootic tissue and over-drastic toxicity, stimulation, anaphylaxis etc. do not occur with the mankind, and with rational effect/risk than the salt that matches.Pharmacologically acceptable salts is well known in the art.For example, S.M.Berge, et al., J.Pharmaceutical Sciences, 1977, among the 66:1 pharmacologically acceptable salts is described in detail.Said salt can be through free alkali functionality and the appropriate organic reaction that makes The compounds of this invention, in final separation and the purge process made acid-stable in situ or the preparation separately of The compounds of this invention.Representational acid salt include but not limited to acetate, adipate, alginates, Citrate trianion, aspartate, benzoate, benzene sulfonate, hydrosulfate, butyrates, camphorate, camsilate, digluconate, glycerophosphate, Hemisulphate, enanthate, hexanoate, fumarate, hydrochloride, hydrobromate, hydriodate, 2-isethionate (different thiosulphate, isothionate), lactic acid salt, PHENRAMINE MALEATE, mesylate, nicotinate, 2-naphthalenesulfonate, oxalate, palmitate, pectate, persulphate, 3-phenylpropionic acid salt, picrate, Pivalate, propionic salt, SUMATRIPTAN SUCCINATE, tartrate, thiocyanate-, phosphoric acid salt, glutaminate, supercarbonate, tosilate and undecane hydrochlorate.Equally, alkaline nitrogen-containing group can use following material quaternized: the muriate of elementary alkyl halide such as methyl, ethyl, propyl group and butyl, bromide and iodide; Sulfuric acid dialkyl such as methyl-sulfate, diethyl ester, dibutylester and diamyl ester; The muriate of long-chain halogenide such as decyl, dodecyl, tetradecyl and octadecyl, bromide and iodide; Arylalkyl halogenide such as bromotoluene and phenethyl bromide and other.Therefore dissolved in or be scattered in the product of water or oil.The sour instance that can be used to form the acceptable acid salt of pharmacy comprises mineral acid example hydrochloric acid, Hydrogen bromide, sulfuric acid and phosphoric acid, and organic acid such as oxalic acid, toxilic acid, succsinic acid and Hydrocerol A.
Base addition salt can contain carboxylic moiety and suitable alkali reaction through what make The compounds of this invention; Final separation and purge process made acid-stable in situ at The compounds of this invention; Described alkali is oxyhydroxide, carbonate and the supercarbonate of the acceptable metallic cation of pharmacy for example, perhaps ammonia or organic primary amine, secondary amine or tertiary amine.
Pharmacologically acceptable salts includes but not limited to based on the positively charged ion of basic metal or earth alkali metal such as lithium, sodium, potassium, calcium, magnesium and aluminium salt etc.; And nontoxic quaternary ammonium and amine positively charged ion, comprise ammonium, tetramethyl-ammonium, tetraethyl ammonium, ammonium methyl, Dimethyl Ammonium, trimethyl ammonium, triethyl ammonium, diethyl ammonium and ethyl ammonium etc.Other representative organic amines that can be used for forming base addition salt comprise quadrol, thanomin, diethylolamine, piperidines, piperazine etc.
Formula I compound of the present invention also comprises its isomer, raceme, enantiomorph, diastereomer, enantiomorph enriched substance, solvate and ester; Formula I compound of the present invention and its isomer, raceme, enantiomorph, diastereomer, enantiomorph enriched substance, solvate and ester can also form solvate, for example hydrate, alcohol adduct etc.Above-claimed cpd can also be prodrug or the form that discharges said activeconstituents in vivo after the metabotic change.Selecting and preparing suitable prodrug derivant is technology as well known to those skilled in the art.In general, for the object of the invention, suitable with non-solvent compound form with the solvate form thereof of pharmacy acceptable solvent such as water, ethanol etc.
Below the activity of the structure of certain exemplary compound of the present invention and anti-HepG2 cell proliferation thereof was listed in, antiproliferative activity measuring method was wherein seen Test Example 1.
| Embodiment number | The compound code name | Inhibiting rate % |
| Embodiment 1 | A | 33.4±3.2 a |
| Embodiment 2 | A-30 | 50.0±3.1 a |
| |
A-31 | 41.9±3.3 a |
| Embodiment 4 | A-32 | 62.6±1.8 a |
| |
A-33 | 53.3±11.5 a |
| Embodiment 6 | A-43 | 50.7±11.7 a |
| Embodiment 7 | A-34 | 88.7±1.1 a |
| Embodiment 8 | A-35 | 86.6±2.4 a |
| Embodiment 9 | A-38 | 63.7±2.0 a |
| Embodiment 10 | A-40 | 84.5±1.9 a |
| Embodiment 11 | A-39 | 70.3±2.6 a |
| Embodiment 12 | A-44 | 69.6±2.5 a |
| Embodiment 13 | A-45 | 50.9±4.3 a |
| Embodiment 14 | A-46 | 53.6±2.2 a |
| Embodiment 15 | A-56 | 88.6±10.8 a |
| Embodiment 16 | A-49 | 86.5±10.6 a |
| Embodiment 17 | A-55 | 93.7±16.1 a |
| Embodiment 18 | A-37 | 62.3±2.0 a |
| Embodiment 19 | A-58 | 92.5±11.4 a |
| Embodiment 20 | A-41 | 8.9±5.1 a |
| Embodiment 21 | A-42 | 56.2±2.0 a |
| Embodiment 22 | A-50 | 87.3±55.5 a |
| Embodiment 23 | A-53 | 87.6±9.8 a |
| Embodiment 24 | A-54 | 93.5±2.5 a |
| Embodiment 25 | A-61 | 86.5±10.6 a |
| Embodiment 26 | A-64 | 79.0±9.9 a |
| Embodiment 27 | A-67 | 70.5±2.5 a |
| Embodiment 28 | A-68 | 63.7±6.1 a |
| Embodiment 29 | A-69 | 88.6±9.1 a |
| Embodiment 30 | A-70 | 76.5±8.4 a |
| Embodiment 31 | A-71 | 58.6±5.3 b |
| Embodiment 32 | A-72 | 49.7±6.1 b |
| Embodiment 33 | A-73 | 58.0±5.6 b |
| Embodiment 34 | A-74 | 59.3±5.1 b |
| Embodiment 35 | A-75 | 57.6±3.6 b |
| Embodiment 36 | A-76 | 52.4±2.3 b |
| Embodiment 37 | A-77 | 52.8±4.1 b |
| Embodiment 38 | A-78 | 50.9±3.5 b |
| Embodiment 39 | A-79 | 48.5±4.3 b |
| Embodiment 40 | A-80 | 49.5±6.0 b |
| Embodiment 41 | A-81 | 57.3±3.6 b |
| Embodiment 42 | A-82 | 43.4±3.2 b |
| Embodiment 43 | A-83 | 56.6±1.2 b |
| Embodiment 44 | A-84 | 53.5±5.6 b |
| Embodiment 45 | A-85 | 60.6±1.2 b |
| Embodiment 46 | A-86 | 54.1±6.0 b |
| Embodiment 47 | A-87 | 13.0±1.3 b |
| Embodiment 48 | A-36 | 32.9±3.0 a |
| Embodiment 49 | A-60 | 5.4±0.9 a |
| Embodiment 50 | A-65 | 87.3±55.5 a |
| Embodiment 51 | A-66 | 87.6±9.8 a |
Annotate a:0.6 μ g/mL b:0.1 μ g/mL
Can change the actual dose level of each activeconstituents in the pharmaceutical composition of the present invention, obtain required therapeutic response so that the active compound amount of gained can effectively be directed against concrete patient, compsn and administering mode.The dosage level fibrous root is according to the severity of the activity of particular compound, route of administration, the patient's condition of treating and wait that the patient's condition and the medical history of treating the patient select.But the way of this area is, the dosage of compound begins from being lower than for obtaining the level that required result of treatment requires, and increases dosage gradually, up to obtaining required effect.
When being used for above-mentioned treating and/or preventing or other treatment and/or when prevention, a kind of The compounds of this invention that treats and/or prevents significant quantity can be used with pure form, perhaps uses with acceptable ester of pharmacy or prodrug forms (under the situation that has these forms).Perhaps, said compound can be accepted the pharmaceutical composition administration of vehicle to contain this purpose compound and one or more medicines.The The compounds of this invention that word " treats and/or prevents significant quantity " refers to the compound of the reasonable effect that is applicable to any therapeutic treatment and/or prevention/risk than the q.s of treatment obstacle.But the total daily dosage portion that it should be understood that The compounds of this invention and compsn must be examined the doctor by the master and maked decision in the medical judgment scope reliably.For any concrete patient, the horizontal fibrous root of concrete treatment effective dose decide according to multiple factor, and said factor comprises the obstacle of being treated and the severity of this obstacle; The activity of the particular compound that is adopted; The concrete compsn that is adopted; Patient's age, body weight, general health situation, sex and diet; The administration time of the particular compound that is adopted, route of administration and excretion rate; The treatment time length; With particular compound combination use of being adopted or the medicine that uses simultaneously; And the known similar factor of medical field.For example, the way of this area is, the dosage of compound begins from being lower than for obtaining the level that required result of treatment requires, and increases dosage gradually, up to obtaining required effect.Generally speaking, formula I compound of the present invention is used for Mammals particularly people's dosage can be between 0.001～1000mg/kg body weight/day, for example between 0.01～100mg/kg body weight/day, for example between 0.01～10mg/kg body weight/day.
The pharmaceutical carrier that utilization those skilled in the art are familiar with can be prepared into the pharmaceutical composition of the The compounds of this invention that contains effective dosage.Therefore the present invention also provides the pharmaceutical composition that comprises with one or more nontoxic drug acceptable carriers The compounds of this invention formulated together.That said pharmaceutical composition can be mixed with especially specially is for oral administration with solid or liquid form, supply the parenteral injection or supply rectal administration.
Described pharmaceutical composition can be mixed with many formulations, is convenient to administration, for example, and oral prepns (like tablet, capsule, solution or suspension); Injectable preparation (like injectable solution or suspension, or injectable dried powder, before injection, adding injection water can use immediately).Carrier comprises in the described pharmaceutical composition: the tackiness agent that oral prepns uses (like starch, normally corn, wheat or rice starch, gelatin, methylcellulose gum, Xylo-Mucine and/or Vinylpyrrolidone polymer), and thinner is (like lactose, Vadex, sucrose, N.F,USP MANNITOL, sorbyl alcohol, Mierocrystalline cellulose; And/or glycerine), lubricant is (like silicon-dioxide, talcum, Triple Pressed Stearic Acid or its salt, normally Magnesium Stearate or calcium stearate; And/or polyoxyethylene glycol); And if desired, also contain disintegrating agent, like starch, agar, Lalgine or its salt; Sodiun alginate normally; And/or effervescent mixture, solubility promoter, stablizer, suspension agent, non-pigment, correctives etc., the sanitas that injectable preparation uses, solubilizing agent, stablizer etc.; The matrix that topical formulations is used, thinner, lubricant, sanitas etc.Pharmaceutical prepn can oral administration or parenteral mode (for example intravenously, subcutaneous, intraperitoneal or part) administration, if some drugs is unsettled under the stomach condition, can it be mixed with enteric coated tablets.
More particularly; But in pharmaceutical composition administered through oral of the present invention, rectum, parenteral, the pond, intravaginal, intraperitoneal, part (as through powder, ointment or drops), a mouthful cheek give the mankind and other Mammalss, perhaps give as oral spray or nasal mist.Term used herein " parenteral " refers to comprise intravenously, intramuscular, intraperitoneal, breastbone is interior, subcutaneous and the administering mode of intra-articular injection and transfusion.
The compsn that is suitable for the parenteral injection can comprise physiologically acceptable aseptic moisture or non-aqueous solution agent, dispersion agent, suspensoid or emulsion, and supplies to reconstitute the aseptic powder of sterile injectable solution agent or dispersion agent.Suitable moisture or nonaqueous carrier, thinner, solvent or vectorial instance comprise water, ethanol, polyvalent alcohol (Ucar 35, polyoxyethylene glycol, glycerine etc.), vegetables oil (like sweet oil), injectable organic ester such as OE and their suitable mixture.
These compsns also can contain auxiliary material, like sanitas, wetting agent, emulsifying agent and dispersion agent.Through various antibacterial agents and anti-mycotic agent, for example parabens, trichloro-butyl alcohol, phenol, Sorbic Acid etc. can guarantee to prevent action of microorganisms.Also expectation comprises isotonic agent, for example carbohydrate, sodium-chlor etc.Through using the material that can postpone absorption, for example aluminum monostearate and gelatin can reach the prolongation absorption of injectable drug form.
Remove the active ingredient beyond the region of objective existence in the suspensoid and also can contain suspension agent, for example ethoxylation i-octadecanol, polyoxyethylene sorbitol and polyoxyethylene sorbitan esters, Microcrystalline Cellulose, the mixture etc. of white lake, wilkinite, agar and tragacanth gum or these materials partially.
In some cases, be the effect of prolong drug, expect to slow down absorption subcutaneous or the intramuscularly medicine.This can realize through the crystal of use poorly water-soluble or the liquid suspension of amorphous substance.Like this, the absorption rate of medicine depends on its dissolution rate, and dissolution rate can be depending on crystallographic dimension and crystal formation.Perhaps, the delay of the medicament forms of parenteral admin absorb through with this medicine dissolution in or be suspended in the oily vehicle and realize.
The injectable depot formulations form can be through at biodegradable polymer such as polylactide-gather the microcapsule matrix that forms medicine in the NSC 403079 (polylactide-polyglycolide) to prepare.Can drug releasing rate be controlled according to the character of medicine with ratio with the concrete polymkeric substance that is adopted of polymkeric substance.The instance of other biological degradable polymer comprises poe class (poly (orthoesters)) and polyanhydrides (poly (anhydrides)).Injectable depot formulations also can through pharmaceutical pack is embedded in can be compatible with bodily tissue liposome or micro emulsion in prepare.
Injectable formulation can be for example through filtering with bacterial filter or sterilizing through the disinfectant that mixes the aseptic solid composite form, and said solids compsn can face with before being dissolved or dispersed in sterilized water or other sterile injectable medium.
The compounds of this invention or its compsn can be with oral methods or parenteral administration modes.Oral administration can be tablet, capsule, seed dressing agent, and the enteron aisle external application preparation has injection and suppository etc.These preparations prepare according to method appreciated by those skilled in the art.In order to make tablet, capsule, the used auxiliary material of seed dressing agent is the auxiliary material of conventional usefulness; For example starch, gelatin, gum arabic; Silica, polyoxyethylene glycol, solvent that liquid dosage form is used such as water, ethanol, Ucar 35, vegetables oil (like Semen Maydis oil, peanut oil, olive wet goods).Contain and also have other auxiliary material in the preparation of The compounds of this invention, tensio-active agent for example, lubricant, disintegrating agent, sanitas, correctives and pigment etc.The dosage that in tablet, capsule, seed dressing agent, injection and suppository, contains formula I compound of the present invention is that the compound amount that exists in unit dosage form is calculated.The general content of formula I compound of the present invention is 0.01-5000mg in unit dosage form, and preferred unit dosage form contains 0.1-500mg, and preferred unit dosage form contains 1-300mg.Specifically, the present invention's solid dosage for oral administration that can provide comprises capsule, tablet, pill, powder and granule.In this type of solid dosage, active compound can be accepted vehicle or carrier such as Trisodium Citrate or Lin Suanergai and/or following material with at least a inert medicine and mix: a) weighting agent or extender such as starch, lactose, sucrose, glucose, mannitol and silicic acid; B) tackiness agent such as CMC 99.5, alginates, gelatin, Vinylpyrrolidone polymer, sucrose and Sudan Gum-arabic; C) wetting Agent for Printing Inks such as glycerine; D) disintegrating agent such as agar, lime carbonate, yam or tapioca(flour), Lalgine, some silicate and yellow soda ash; E) solution retarding agent such as paraffin; F) absorb accelerator such as quaternary ammonium compound; G) wetting agent such as Tego Alkanol 16 and Zerol; H) sorbent material such as kaolin and wilkinite and i) lubricant such as talcum powder, calcium stearate, Magnesium Stearate, solid polyethylene glycol, sodium lauryl sulphate and their mixture.Under the situation of capsule, tablet and pill, also can comprise buffer reagent in the said formulation.
The solids compsn of similar type uses vehicle for example lactose and high molecular weight polyethylene glycol etc., also can be used as the weighting material in soft capsule and the hard capsule.
The solid dosage of tablet, dragee (dragees), capsule, pill and granule can prepare with dressing and shell material such as enteric coating material and known other clothing materials of field of medicine preparations.These solid dosages can be chosen wantonly and contain opalizer, and its composition also can make it just or preferentially choose wantonly with the delayed mode release of active ingredients at certain position of enteron aisle.The instance of operable embedding composition comprises polymer substance and wax class.If be fit to, active compound also can be made into the micro-capsule form with one or more above-mentioned vehicle.
Liquid dosage form for oral administration comprises the acceptable emulsion of pharmacy, solution, suspensoid, syrup and elixir.Liquid dosage form also can contain this area inert diluent commonly used except that containing the active ingredient beyond the region of objective existence; For example water or other solvents; Solubilizing agent and emulsifying agent be ethanol, Virahol, ethyl-carbonate, ETHYLE ACETATE, benzylalcohol, peruscabin, Ucar 35,1,3 butylene glycol, N, oils (particularly Oleum Gossypii semen, peanut oil, Semen Maydis oil, germ oil, sweet oil, Viscotrol C and til), glycerine, tetrahydrofurfuryl alcohol (tetrahydrofurfuryl alcohol), polyoxyethylene glycol and the fatty ester of sorbitan and their mixture for example.Oral compsns also can comprise auxiliary material except that comprising inert diluent, for example wetting agent, emulsifying agent and suspension agent, sweeting agent, correctives and flavouring agent.
The compsn of confession rectum or vagina administration is suppository preferably.Suppository can be through for example theobroma oil, polyoxyethylene glycol or suppository wax are mixed and prepared with The compounds of this invention and suitable non-irritating excipient or carrier; They at room temperature are solid; Therefore but next at body temperature is liquid, can in rectal cavity or vaginal canal, melt and discharges active compound.
Compound of the present invention and compsn thereof also consider to be used for topical.Supply the dosage form of topical administration The compounds of this invention to comprise powder, sprays, ointment and inhalation.Under aseptic condition with active compound and pharmaceutically acceptable carrier and any required sanitas, buffer reagent or propellant mixing.Ophthalmic preparation, eye ointment, powder and solution also are considered within the scope of the present invention.
The compounds of this invention also can the liposome form administration.As well known in the art, liposome makes with phosphatide or other lipid materials usually.Liposome is formed by the single or multiple lift aquation liquid crystal that is scattered in the water-bearing media.Can accept on any nontoxic, physiology that can form liposome and metabolizable lipid all can use.The present composition of liposome form also can contain stablizer, sanitas, vehicle etc. except that containing The compounds of this invention.Preferred lipid is natural and synthetic phosphatide and phosphatidylcholine (Yelkin TTS), and their can use separately or together.The method that forms liposome is well known in the art.Referring to for example Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p.33.
The inventor is surprised to find, and the cyclisation berberinc derivate shown in the structural formula I has produced the obvious suppression effect to the propagation of HepG2 cell.Therefore, compound of the present invention can be used for treating and/or preventing Mammals (comprising the people) tumour or cancer property disease (for example liver cancer).
Description of drawings
Fig. 1 has described The compounds of this invention the drug-resistant tumor cell activity has been measured the result.
Fig. 2 has described the cell cycle analysis of The compounds of this invention and has measured the result.
Fig. 3 has described the inhibition determination of activity result of The compounds of this invention to topoisomerase I.
Embodiment
Further specify the present invention through concrete preparation embodiment and biological test example below, still, be to be understood that into, these embodiment and Test Example are only used for the usefulness of explanation more in detail particularly, are used for limiting in any form the present invention and should not be construed as.
The present invention carries out generality and/or concrete description to the material and the TP that are used in the test.Though for realizing that employed many materials of the object of the invention and working method are well known in the art, the present invention still does to describe in detail as far as possible at this.It will be apparent to those skilled in the art that hereinafter, if do not specify that material therefor of the present invention and working method are well known in the art.
Embodiment 1: compd A synthetic
To be dissolved with Peng Qinghuana (1.2g, 5% sodium hydroxide solution (10ml) 32mmol) dropwise be added to contain Berberine (7.4g, 20mmol) and salt of wormwood (8.3g; In methyl alcohol 60mmol) (250ml) solution system; Stirring at room 2 hours, suction filtration is collected the yellow-green colour solid of separating out, and filter cake is used zero(ppm) water (100ml) and 80% ethanol (100ml) washing successively; Obtain midbody dihydroberberine (4.2g, 62%).(4.0g 12mmol) is dissolved in the acetonitrile (160ml), adds the oxalic dialdehyde (2ml) of acetate (40ml) and 40% then, is heated to 85～95 ℃ and refluxes 5 hours with the midbody dihydroberberine; The flaggy monitoring reaction is complete, and reaction solution is concentrated, and obtains scarlet oily matter, adds 2% hydrochloric acid soln (200ml); Stirring at room 1 hour is filtered, filtrating stirring at room 5 days; Reaction solution is concentrated, use 95% ethyl alcohol recrystallization, products therefrom washs with ether; Get orange solids A (1.8g, 38%), fusing point: 185～187 ℃.
HRMS-ESI(M/Z)：360.1216【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.8Hz，2H)，4.12(s，3H)，4.16(s，3H)，5.24(t，J＝6.8Hz，2H)，6.39(s，2H)，7.59(s，1H)，8.21(d，J＝9.2Hz，1H)，8.31(d，J＝9.6Hz，1H)，8.85(d，J＝9.6Hz，1H)，8.89(d，J＝9.2Hz，1H)，10.14(s，1H).
Embodiment 2: compd A-30 synthetic
(3.6g 9.1mmol) places the 250ml round-bottomed flask, and maintenance vacuum tightness is 30～40mmHg with A; Be heated to 195～210 ℃ of reactions 30 minutes; The solid color is deepened gradually, all becomes scarlet at last, and (5ml: 95ml) acidifying obtains red product A-30 (3.2g to acidic alcohol; 92%) fusing point: 269～271 ℃.
HRMS-ESI(M/Z)：346.1069【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.56(t，J＝6.8Hz，2H)，4.03(s，3H)，5.10(t，J＝6.8Hz，2H)，6.36(s，2H)，7.52(s，1H)，8.02(d，J＝8.8Hz，1H)，8.10(d，J＝9.2Hz，1H)，8.26(d，J＝8.4Hz，1H)，8.75(d，J＝9.2Hz，1H)，9.96(s，1H).
Embodiment 3: compd A-31 synthetic
With A-30 (198mg 0.52mmol) is dissolved in DMF (10ml), add then porphyrize Pottasium Hydroxide (60mg, 1.04mmol) and monobromethane (2ml; 27mmol), be heated to 60 ℃ of reactions 12 hours, concentrating under reduced pressure removes and desolvates, and resistates is transferred PH to 3 with Hydrogen chloride; Suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column; Obtain red product A-31 (52mg, 22%), fusing point: 216～218 ℃.
HRMS-ESI(M/Z)：374.1397【M-Br】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ1.49(t，J＝7.2Hz，3H)，3.62(t，J＝6.8Hz，2H)，4.10(s，3H)，4.44(q，J＝7.2Hz，2H)，5.26(t，J＝6.8Hz，2H)，6.39(s，2H)，7.58(s，1H)，8.20(d，J＝9.2Hz，1H)，8.29(d，J＝9.2Hz，1H)，8.83(d，J＝9.2Hz，1H)，8.88(d，J＝9.2Hz，1H)，10.05(s，1H).
Embodiment 4: compd A-32 synthetic
With A-30 (198mg 0.52mmol) is dissolved in DMF (10ml), add then porphyrize Pottasium Hydroxide (60mg, 1.04mmol) with 1-butyl iodide (236 μ l; 2.08mmol), being heated to 60 ℃ of reactions 12 hours, concentrating under reduced pressure removes and desolvates, and resistates is transferred PH to 3 with Hydrogen chloride; Suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column; Obtain red product A-32 (75mg, 27%), fusing point: 202～204 ℃.
HRMS-ESI(M/Z)：402.1702【M-I】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ1.00(t，J＝7.2Hz，3H)，1.51-1.57(m，2H)，1.87-1.94(m，2H)，3.62(t，J＝6.8Hz，2H)，4.10(s，3H)，4.37(t，J＝6.8Hz，2H)，5.25(t，J＝6.8Hz，2H)，6.40(s，2H)，7.59(s，1H)，8.22(d，J＝9.2Hz，1H)，8.30(d，J＝9.2Hz，1H)，8.84(d，J＝9.2Hz，1H)，8.89(d，J＝9.2Hz，1H)，9.98(s，1H).
Embodiment 5: compd A-33 synthetic
With A-30 (99mg 0.26mmol) is dissolved in DMF (5ml), add then porphyrize Pottasium Hydroxide (30mg, 0.52mmol) and cylite (124 μ l; 1.04mmol), being heated to 60 ℃ of reactions 12 hours, concentrating under reduced pressure removes and desolvates, and resistates is transferred PH to 3 with Hydrogen chloride; Suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column; Obtain orange product A-33 (81mg, 60%), fusing point: 131～133 ℃.
HRMS-ESI(M/Z)：436.1562【M-Br】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.8Hz，2H)，4.14(s，3H)，5.22(t，J＝6.8Hz，2H)，5.43(s，2H)，6.39(s，2H)，7.35-7.43(m，3H)，7.59(s，1H)，7.62(d，J＝6.8Hz，2H)，8.21(d，J＝9.2Hz，1H)，8.32(d，J＝9.6Hz，1H)，8.86(t，J＝9.2Hz，2H)，9.98(s，1H).
Embodiment 6: compd A-43 synthetic
(99mg 0.26mmol) is dissolved in DMF (5ml), and (30mg is 0.52mmol) with 2 to add the Pottasium Hydroxide of porphyrize then with A-30; (134 μ l 1.04mmol), are heated to 60 ℃ of reactions 12 hours to 4-difluoro bromobenzyl, and concentrating under reduced pressure removes and desolvates; Resistates is transferred PH to 3 with Hydrogen chloride, and suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column; Obtain red product A-43 (79mg, 55%), fusing point: 138～140 ℃.
HRMS-ESI(M/Z)：472.1347【M-Br】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.8Hz，2H)，4.11(s，3H)，5.22(t，J＝6.8Hz，2H)，5.47(s，2H)，6.40(s，2H)，7.14-7.19(m，1H)，7.28-7.33(m，1H)，7.60(s，1H)，7.81(q，J＝8.4Hz，1H)，8.22(d，J＝9.2Hz，1H)，8.33(d，J＝9.6Hz，1H)，8.88(d，J＝4.4Hz，1H)，8.90(d，J＝4.0Hz，1H)，9.93(s，1H).
Embodiment 7: compd A-34 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (74 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add Acetyl Chloride 98Min. then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-34 (70mg, 64%), fusing point: 183～185 ℃.
HRMS-ESI(M/Z)：388.1188【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ2.56(s，3H)，3.64(t，J＝6.8Hz，2H)，4.09(s，3H)，5.24(t，J＝6.8Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.26(d，J＝9.2Hz，1H)，8.40(d，J＝9.2Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.09(d，J＝9.2Hz，1H)，10.15(s，1H).
Embodiment 8: compd A-35 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (120 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add Benzoyl chloride 99min. then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains orange product A-35 (84mg, 67%), fusing point: 228～230 ℃.
HRMS-ESI(M/Z)：450.1336【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.8Hz，2H)，4.07(s，3H)，5.22(t，J＝6.8Hz，2H)，6.41(s，2H)，7.60(s，1H)，7.71(t，J＝7.6Hz，2H)，7.86(t，J＝7.6Hz，1H)，8.26-8.31(m，3H)，8.46(d，J＝9.6Hz，1H)，8.98(d，J＝9.6Hz，1H)，9.15(d，J＝9.2Hz，1H)，10.24(s，1H).
Embodiment 9: compd A-38 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes with A-30; (84 μ l 1.04mmol), add methyl benzoyl chloride (139 μ l then to add anhydrous pyridine; 1.04mmol), continuing to reflux 6 hours, the flaggy monitoring reaction is complete.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-38 (53mg, 41%), fusing point: 221～223 ℃.
HRMS-ESI(M/Z)：464.1489【M-Cl】
+
1H?NMR(CD
3OD，400MHz)：δ2.47(s，3H)，3.60(t，J＝6.8Hz，2H)，4.06(s，3H)，5.17(t，J＝6.8Hz，2H)，6.29(s，2H)，7.40(s，1H)，7.43(d，J＝8.0Hz，2H)，8.19(d，J＝8.0Hz，2H)，8.27(d，J＝9.6Hz，1H)，8.32(d，J＝9.6Hz，1H)，8.76(d，J＝9.2Hz，1H)，8.96(d，J＝9.2Hz，1H)，9.89(s，1H).
Embodiment 10: compd A-40 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes with A-30; (84 μ l 1.04mmol), add anisoyl chloride (141 μ l then to add anhydrous pyridine; 1.04mmol), continuing to reflux 6 hours, the flaggy monitoring reaction is complete.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains orange product A-40 (69mg, 51%), fusing point: 202～204 ℃.
HRMS-ESI(M/Z)：480.1442【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.8Hz，2H)，3.92(s，3H)，4.06(s，3H)，5.22(t，J＝6.8Hz，2H)，6.41(s，2H)，7.22(d，J＝8.8Hz，2H)，7.59(s，1H)，8.24(d，J＝8.8Hz，2H)，8.27(d，J＝9.6Hz，1H)，8.44(d，J＝9.2Hz，1H)，8.98(d，J＝9.6Hz，1H)，9.13(d，J＝9.6Hz，1H)，10.20(s，1H).
Embodiment 11: compd A-39 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), being warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add then that (123 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to fluorobenzoyl chloride to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains orange product A-39 (40mg, 31%), fusing point: 218～220 ℃.
HRMS-ESI(M/Z)：468.1256【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.4Hz，2H)，4.08(s，3H)，5.21(t，J＝6.4Hz，2H)，6.41(s，2H)，7.56(t，J＝8.8Hz，2H)，7.60(s，1H)，8.28(d，J＝9.2Hz，1H)，8.35-8.39(m，2H)，8.46(d，J＝9.6Hz，1H)，8.99(d，J＝9.2Hz，1H)，9.16(d，J＝9.6Hz，1H)，10.24(s，1H).
Embodiment 12: compd A-44 synthetic
(193mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with 4-fluoro-3-nitrobenzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-44 (35mg, 25%), fusing point: 187～189 ℃.
HRMS-ESI(M/Z)：513.1083【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，4.09(s，3H)，5.20(t，J＝6.4Hz，2H)，6.41(s，2H)，7.61(s，1H)，7.93-7.98(m，1H)，8.29(d，J＝9.2Hz，1H)，8.48(d，J＝9.2Hz，1H)，8.67-8.68(m，1H)，8.94(dd，J＝2.0，7.2Hz，1H)，8.99(d，J＝9.2Hz，1H)，9.18(d，J＝9.6Hz，1H)，10.29(s，1H).
Embodiment 13: compd A-45 synthetic
(188mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with 4-methyl-3-nitro phenylformic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains scarlet product A-45 (36mg, 25%), fusing point: 165～167 ℃.
HRMS-ESI(M/Z)：509.1343【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ2.70(s，3H)，3.62(t，J＝6.8Hz，2H)，4.08(s，3H)，5.20(t，J＝6.8Hz，2H)，6.41(s，2H)，7.61(s，1H)，7.87(d，J＝8.0Hz，1H)，8.28(d，J＝9.2Hz，1H)，8.47(d，J＝9.2Hz，2H)，8.79(d，J＝1.2Hz，1H)，8.99(d，J＝9.6Hz，1H)，9.17(d，J＝9.2Hz，1H)，10.27(s，1H).
Embodiment 14: compd A-46 synthetic
(205mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with 4-methoxyl group-3-nitrobenzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains scarlet product A-46 (22mg, 15%), fusing point: 158～160 ℃.
HRMS-ESI(M/Z)：525.1295【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，4.08(s，3H)，4.11(s，3H)，5.20(t，J＝6.4Hz，2H)，6.41(s，2H)，7.60(s，1H)，7.68(d，J＝8.8Hz，1H)，8.28(d，J＝9.2Hz，1H)，8.46(d，J＝9.6Hz，1H)，8.51(dd，J＝2.4，8.8Hz，1H)，8.74(d，J＝2.4Hz，1H)，8.98(d，J＝9.6Hz，1H)，9.16(d，J＝9.2Hz，1H)，10.25(s，1H).
Embodiment 15: compd A-56 synthetic
(173mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with piperinic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains orange product A-56 (29mg, 21%), fusing point: 192～194 ℃.
HRMS-ESI(M/Z)：494.1239【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.4Hz，2H)，4.07(s，3H)，5.23(t，J＝6.4Hz，2H)，6.25(s，2H)，6.41(s，2H)，7.22(d，J＝8.0Hz，1H)，7.60(s，1H)，7.73(d，J＝1.6Hz，1H)，7.91(dd，J＝1.6，8.4Hz，1H)，8.27(d，J＝9.2Hz，1H)，8.44(d，J＝9.6Hz，1H)，8.97(d，J＝9.6Hz，1H)，9.13(d，J＝9.6Hz，1H)，10.19(s，1H).
Embodiment 16: compd A-49 synthetic
With 3,4, (221mg 1.04mmol) is added in the thionyl chloride (5ml) the 5-trimethoxybenzoic acid, refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains orange product A-49 (31mg, 21%), fusing point: 210～212 ℃.
HRMS-ESI(M/Z)：540.1685【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，3.83(s，3H)，3.92(s，6H)，4.08(s，3H)，5.24(t，J＝6.4Hz，2H)，6.41(s，2H)，7.56(s，2H)，7.60(s，1H)，8.28(d，J＝9.2Hz，1H)，8.46(d，J＝9.6Hz，1H)，8.99(d，J＝9.2Hz，1H)，9.16(d，J＝9.6Hz，1H)，10.20(s，1H).
Embodiment 17: compd A-55 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (124 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add o-fluoro-benzoyl chloride then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-55 (35mg, 27%), fusing point: 181～183 ℃.
HRMS-ESI(M/Z)：468.1247【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.8Hz，2H)，4.10(s，3H)，5.22(t，J＝6.8Hz，2H)，6.41(s，2H)，7.51-7.57(m，2H)，7.60(s，1H)，7.88-7.92(m，1H)，8.28(d，J＝9.2Hz，1H)，8.30-8.32(m，1H)，8.46(d，J＝9.2Hz，1H)，8.98(d，J＝9.2Hz，1H)，9.16(d，J＝9.2Hz，1H)，10.25(s，1H).
Embodiment 18: compd A-37 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (132 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add NSC 93897 then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-37 (31mg, 23%), fusing point: 164～166 ℃.
HRMS-ESI(M/Z)：484.0952【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.63(t，J＝6.8Hz，2H)，4.11(s，3H)，5.24(t，J＝6.8Hz，2H)，6.41(s，2H)，7.61(s，1H)，7.66-7.69(m，1H)，7.79-7.81(m，2H)，8.28(d，J＝9.2Hz，1H)，8.45-8.48(m，2H)，8.99(d，J＝9.6Hz，1H)，9.16(d，J＝9.2Hz，1H)，10.24(s，1H).
Embodiment 19: compd A-58 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and adds anhydrous pyridine (84 μ l with A-30; 1.04mmol), add 2,4 difluorobenzene formyl chloride (128 μ l then; 1.04mmol), continuing to reflux 6 hours, the flaggy monitoring reaction is complete.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-58 (23mg, 17%), fusing point: 191～193 ℃.
HRMS-ESI(M/Z)：486.1151【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，4.10(s，3H)，5.21(t，J＝6.4Hz，2H)，6.41(s，2H)，7.41-7.46(m，1H)，7.61(s，1H)，7.62-7.68(m，1H)，8.28(d，J＝9.2Hz，1H)，8.39(q，J＝8.4Hz，1H)，8.46(d，J＝9.6Hz，1H)，8.98(d，J＝9.6Hz，1H)，9.16(d，J＝9.6Hz，1H)，10.24(s，1H).
Embodiment 20: compd A-41 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes with A-30; (84 μ l 1.04mmol), add 4-acetamido benzene sulfonyl chloride (243mg then to add anhydrous pyridine; 1.04mmol), continuing to reflux 6 hours, the flaggy monitoring reaction is complete.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-41 (23mg, 15%), fusing point: 205～207 ℃.
HRMS-ESI(M/Z)：543.1203【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ2.12(s，3H)，3.60(t，J＝6.4Hz，2H)，3.81(s，3H)，5.18(t，J＝6.4Hz，2H)，6.42(s，2H)，7.63(s，1H)，7.86(s，4H)，8.28(d，J＝9.2Hz，1H)，8.34(d，J＝9.6Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.15(d，J＝9.6Hz，1H)，9.74(s，1H)，10.61(s，1H).
Embodiment 21: compd A-42 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (133 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add benzene sulfonyl chloride then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-42 (38mg, 28%), fusing point: 223～225 ℃.
HRMS-ESI(M/Z)：486.1001【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.8Hz，2H)，3.76(s，3H)，5.20(t，J＝6.8Hz，2H)，6.42(s，2H)，7.63(s，1H)，7.73(t，J＝8.0Hz，2H)，7.91(t，J＝7.6Hz，1H)，7.97(d，J＝7.2Hz，2H)，8.28(d，J＝9.6Hz，1H)，8.33(d，J＝9.6Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.16(d，J＝9.6Hz，1H)，9.79(s，1H).
Embodiment 22: compd A-50 synthetic
(179mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with n-capric acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-50 (25mg, 18%), fusing point: 180～182 ℃.
HRMS-ESI(M/Z)：500.2444【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ0.85-0.88(m，3H)，1.23-1.49(m，12H)，1.73-1.80(m，2H)，2.89(t，J＝7.2Hz，2H)，3.64(t，J＝6.8Hz，2H)，4.07(s，3H)，5.24(t，J＝6.8Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.26(d，J＝9.2Hz，1H)，8.40(d，J＝9.2Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.08(d，J＝9.6Hz，1H)，10.11(s，1H).
Embodiment 23: compd A-53 synthetic
(208mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with LAURIC ACID 99 MIN.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-53 (21mg, 14%), fusing point: 184～186 ℃.
HRMS-ESI(M/Z)：528.2718【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ0.85(t，J＝6.8Hz，3H)，1.25-1.47(m，16H)，1.74-1.78(m，2H)，2.89(t，J＝7.2Hz，2H)，3.64(t，J＝6.8Hz，2H)，4.07(s，3H)，5.23(t，J＝6.8Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.26(d，J＝9.6Hz，1H)，8.40(d，J＝9.6Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.09(d，J＝9.6Hz，1H)，10.09(s，1H).
Embodiment 24: compd A-54 synthetic
(267mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with palmitinic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-54 (52mg, 32%), fusing point: 184～186 ℃.
HRMS-ESI(M/Z)：584.3337【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ0.84(t，J＝6.8Hz，3H)，1.23-1.47(m，24H)，1.74-1.78(m，2H)，2.89(t，J＝7.2Hz，2H)，3.64(t，J＝6.4Hz，2H)，4.07(s，3H)，5.23(t，J＝6.4Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.26(d，J＝9.2Hz，1H)，8.40(d，J＝9.6Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.09(d，J＝9.6Hz，1H)，10.09(s，1H).
Embodiment 25: compd A-61 synthetic
(99mg 0.26mmol) is dissolved in DMF (5ml), and (30mg is 0.52mmol) with 1 to add the Pottasium Hydroxide of porphyrize then with A-30; (90 μ l 1.04mmol), are heated to 60 ℃ of reactions 12 hours to the 2-ethylene dibromide, and concentrating under reduced pressure removes and desolvates; Resistates is transferred PH to 3 with Hydrogen chloride, and suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column; Obtain red product A-61 (40mg, 29%), fusing point: 142～144 ℃.
HRMS-ESI(M/Z)：452.0476【M-Br】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.65(t，J＝6.4Hz，2H)，4.02(t，J＝6.0Hz，2H)，4.13(s，3H)，4.70(t，J＝6.0Hz，2H)，5.25(t，J＝6.4Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.24(d，J＝9.2Hz，1H)，8.34(d，J＝9.2Hz，1H)，8.90(d，J＝8.8Hz，1H)，8.92(d，J＝8.8Hz，1H)，10.11(s，1H).
Embodiment 26: compd A-64 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (91 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add bromoacetyl bromide then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-64 (42mg, 30%), fusing point: 154～156 ℃.
HRMS-ESI(M/Z)：466.0293【M-Br】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.65(t，J＝6.8Hz，2H)，4.10(s，3H)，4.78(s，2H)，5.20(t，J＝6.8Hz，2H)，6.41(s，2H)，7.62(s，1H)，8.27(d，J＝9.2Hz，1H)，8.42(d，J＝9.2Hz，1H)，8.96(d，J＝9.2Hz，1H)，9.13(d，J＝9.6Hz，1H)，10.17(s，1H).
Embodiment 27: compd A-67 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (144 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add caproyl chloride then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-67 (54mg, 43%), fusing point: 125～127 ℃.
HRMS-ESI(M/Z)：444.1824【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ0.94(t，J＝7.2Hz，3H)，1.38-1.46(m，4H)，1.76-1.79(m，2H)，2.89(t，J＝7.2Hz，2H)，3.64(t，J＝6.4Hz，2H)，4.08(s，3H)，5.23(t，J＝6.4Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.26(d，J＝9.2Hz，1H)，8.40(d，J＝9.2Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.09(d，J＝9.2Hz，1H)，10.10(s，1H).
Embodiment 28: compd A-68 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (161 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add oenanthyl chloro then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains orange product A-68 (46mg, 36%), fusing point: 117～119 ℃.
HRMS-ESI(M/Z)：458.1953【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ0.91(t，J＝7.2Hz，3H)，1.34-1.38(m，4H)，1.46-1.50(m，2H)，1.75-1.78(m，2H)，2.90(t，J＝7.2Hz，2H)，3.64(t，J＝6.8Hz，2H)，4.07(s，3H)，5.24(t，J＝6.8Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.25(d，J＝9.2Hz，1H)，8.39(d，J＝9.2Hz，1H)，8.94(d，J＝9.6Hz，1H)，9.08(d，J＝9.2Hz，1H)，10.13(s，1H).
Embodiment 29: compd A-69 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (178 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add capryl(yl)chloride then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains orange product A-69 (69mg, 52%), fusing point: 118～120 ℃.
HRMS-ESI(M/Z)：472.2121【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ0.89(t，J＝6.8Hz，3H)，1.31-1.39(m，6H)，1.45-1.49(m，2H)，1.75-1.79(m，2H)，2.90(t，J＝7.2Hz，2H)，3.64(t，J＝6.8Hz，2H)，4.07(s，3H)，5.24(t，J＝6.8Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.26(d，J＝9.6Hz，1H)，8.40(d，J＝9.2Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.08(d，J＝9.2Hz，1H)，10.11(s，1H).
Embodiment 30: compd A-70 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l, 1.04mmol), (195 μ l 1.04mmol), continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add pelargonyl chloride then to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-70 (39mg, 29%), fusing point: 126～128 ℃.
HRMS-ESI(M/Z)：486.2262【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ0.88(t，J＝6.8Hz，3H)，1.23-1.47(m，10H)，1.75-1.78(m，2H)，2.90(t，J＝7.2Hz，2H)，3.64(t，J＝6.4Hz，2H)，4.07(s，3H)，5.25(t，J＝6.4Hz，2H)，6.40(s，2H)，7.60(s，1H)，8.23(d，J＝9.2Hz，1H)，8.38(d，J＝9.6Hz，1H)，8.92(d，J＝9.6Hz，1H)，9.06(d，J＝9.6Hz，1H)，10.14(s，1H).
Embodiment 31: compd A-71 synthetic
(209mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with 3-nitro-4-chloro-benzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-71 (63mg, 46%), fusing point: 211～213 ℃.
HRMS-ESI(M/Z)：529.07968【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，4.08(s，3H)，5.19(t，J＝6.4Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.15(d，J＝8.4Hz，1H)，8.28(d，J＝9.6Hz，1H)，8.48(d，J＝9.6Hz，1H)，8.53(dd，J＝2.0，8.4Hz，1H)，8.91(d，J＝1.6Hz，1H)，8.99(d，J＝9.6Hz，1H)，9.18(d，J＝9.6Hz，1H)，10.28(s，1H).
Embodiment 32: compd A-72 synthetic
(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes with A-30; (84 μ l 1.04mmol), add 4-cyanic acid benzene sulfonyl chloride (210mg then to add anhydrous pyridine; 1.04mmol), continuing to reflux 6 hours, the flaggy monitoring reaction is complete.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-72 (74mg, 56%), fusing point: 216～219 ℃.
HRMS-ESI(M/Z)：511.09638【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.64(t，J＝6.4Hz，2H)，3.75(s，3H)，5.25(t，J＝6.4Hz，2H)，6.42(s，2H)，7.64(s，1H)，8.16-8.24(m，4H)，8.28(d，J＝9.2Hz，1H)，8.33(d，J＝9.2Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.18(d，J＝9.6Hz，1H)，9.88(s，1H).
Embodiment 33: compd A-73 synthetic
(254mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with 2-bromo-5-nitrobenzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes with A-30; (84 μ l 1.04mmol), divide cooling to add anhydrous pyridine; Suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column; Obtain red product A-73 (62mg, 46%), fusing point: 180～183 ℃.
HRMS-ESI(M/Z)：573.02972【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.64(t，J＝6.8Hz，2H)，4.07(s，3H)，5.23(t，J＝6.8Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.23(d，J＝7.8Hz，1H)，8.28(d，J＝9.6Hz，1H)，8.48(d，J＝9.6Hz，1H)，8.51(dd，J＝1.6，7.8Hz，1H)，8.93(d，J＝1.6Hz，1H)，8.96(d，J＝9.6Hz，1H)，9.18(d，J＝9.6Hz，1H)，10.36(s，1H).
Embodiment 34: compd A-74 synthetic
(192mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with 2-fluoro-5-nitrobenzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-74 (40mg, 30%), fusing point: 209～211 ℃.
HRMS-ESI(M/Z)：513.11096【M-Cl】
+
1H?NMR(CD3SOCD
3，400MHz)：δ3.63(t，J＝6.4Hz，2H)，4.11(s，3H)，5.20(t，J＝6.4Hz，2H)，6.42(s，2H)，7.61(s，1H)，7.89(t，J＝10.0Hz，1H)，8.28(d，J＝9.2Hz，1H)，8.48(d，J＝9.2Hz，1H)，8.74-8.76(mm，1H)，8.99(d，J＝9.2Hz，1H)，9.02(d，J＝3.2Hz，1H)，9.19(d，J＝9.6Hz，1H)，10.30(s，1H).
Embodiment 35: compd A-75 synthetic
(117mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 2-furancarboxylic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-75 (29mg, 26%), fusing point: 186～188 ℃.
HRMS-ESI(M/Z)：529.07968【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，4.08(s，3H)，5.23(t，J＝6.4Hz，2H)，6.40(s，2H)，6.93(q，J＝1.6Hz，1H)，7.59(s，1H)，7.77(d，J＝3.6Hz?1H)，8.21-8.25(m，2H)，8.42(d，J＝9.6Hz，1H)，8.92(d，J＝9.6Hz，1H)，9.11(d，J＝9.2Hz，1H)，10.22(s，1H).
Embodiment 36: compd A-76 synthetic
(174mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 3-nitrobenzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-76 (52mg, 41%), fusing point: 221～223 ℃.
HRMS-ESI(M/Z)：495.12041【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，4.09(s，3H)，5.20(t，J＝6.4Hz，2H)，6.41(s，2H)，7.60(s，1H)，8.01-8.05(m，1H)，8.28(d，J＝9.2Hz，1H)，8.48(d，J＝9.2Hz，1H)，8.69-8.71(m，2H)，8.97-9.0(m，2H)9.18(d，J＝9.2Hz，1H)，10.32(s，1H).
Embodiment 37: compd A-77 synthetic
(163mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 4-chloro-benzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-77 (48mg, 38%), fusing point: 198～201 ℃.
HRMS-ESI(M/Z)：484.09596【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.4Hz，2H)，4.07(s，3H)，5.21(t，J＝6.4Hz，2H)，6.30(s，2H)，7.60(s，1H)，7.80(d，J＝8.4Hz，2H)，8.24(d，J＝9.2Hz，1H)，8.30(d，J＝8.4Hz，2H)，8.44(d，J＝9.2Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.13(d，J＝9.6Hz，1H)，10.25(s，1H).
Embodiment 38: compd A-78 synthetic
(141mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 3-tolyl acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-78 (57mg, 48%), fusing point: 205～208 ℃.
HRMS-ESI(M/Z)：464.15097【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ2.49(s，3H)，3.62(t，J＝6.8Hz，2H)，4.07(s，3H)，5.23(t，J＝6.4Hz，2H)，6.41(s，2H)，7.60(s，1H)，7.62-769.(m，2H)，8.09-8.13(m，2H)，8.23(d?J＝8.4Hz，1H)，8.43(d，J＝8.4Hz，1H)，8.94(d，J＝8.4Hz，1H)，9.11(d，J＝8.4Hz，1H)，10.24(s，1H).
Embodiment 39: compd A-79 synthetic
(141mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 2-tolyl acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-79 (50mg, 42%), fusing point: 200～202 ℃.
HRMS-ESI(M/Z)：464.15110【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ2.66(s，3H)，3.62(t，J＝6.0Hz，2H)，4.09(s，3H)，5.24(t，J＝6.0Hz，2H)，6.40(s，2H)，7.51-7.54(m，2H)，7.59(s，1H)，7.69(t，J＝7.6Hz，1H)，8.24(d?J＝9.2Hz，1H)，8.37(d?J＝7.6Hz，1H)，8.44(d，J＝9.2Hz，1H)，8.95(d，J＝9.6Hz，1H)，9.11(d，J＝9.6Hz，1H)，10.24(s，1H).
Embodiment 40: compd A-80 synthetic
(163mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with 5-nitro-2-furancarboxylic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-80 (29mg, 27%), fusing point: 190～192 ℃.
HRMS-ESI(M/Z)：485.09969【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.63(t，J＝6.4Hz，2H)，4.11(s，3H)，5.20(t，J＝6.4Hz，2H)，6.41(s，2H)，7.61(s，1H)，8.02-8.06(m，2H)，8.25(d，J＝8.4Hz，1H)，8.46(d，J＝8.4Hz，1H)，8.96(d，J＝8.4Hz，1H)，9.17(d，J＝8.4Hz，1H)，10.30(s，1H).
Embodiment 41: compd A-81 synthetic
(222mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 4-phenoxy benzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-81 (59mg, 42%), fusing point: 199～202 ℃.
HRMS-ESI(M/Z)：529.07968【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.4Hz，2H)，4.06(s，3H)，5.23(t，J＝6.4Hz，2H)，6.40(s，2H)，7.20-7.23(m，4H)，7.30(t，J＝7.6Hz，1H)，7.52(t，J＝8Hz，2H)，7.59(s，1H)，8.22(d，J＝8.8Hz，1H)，8.30(d，J＝8.4Hz，2H)，8.42(d，J＝9.2Hz，1H)，8.92(d，J＝8.8Hz，1H)，9.09(d，J＝9.2Hz，1H)，10.22(s，1H).
Embodiment 42: compd A-82 synthetic
(160mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 4-fluorophenylacetic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-82 (43mg, 34%), fusing point: 195～198 ℃.
HRMS-ESI(M/Z)：482.14194【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.66(t，J＝6.8Hz，2H)，4.08(s，3H)，4.31(s，2H)，5.26(t，J＝6.8Hz，2H)，6.41(s，2H)，7.23-7.30(m，2H)，7.51-7.55(m，2H)，7.62(s，1H)，8.26(d，J＝9.6Hz，1H)，8.38(d，J＝9.6Hz，1H)，8.94(d，J＝9.2Hz，1H)，9.09(d，J＝9.6Hz，1H)，10.20(s，1H).
Embodiment 43: compd A-83 synthetic
(162mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 3-chloro-benzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-83 (63mg, 50%), fusing point: 183～185 ℃.
HRMS-ESI(M/Z)：484.09598【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，4.08(s，3H)，5.22(t，J＝6.4Hz，2H)，6.40(s，2H)，7.60(s，1H)，7.74-7.79(m，1H)，7.94-7.97(m，1H)，8.22-8.26(m，2H)，8.30(s，1H)，8.43(d，J＝9.2Hz，1H)，8.93(d，J＝9.2Hz，1H)，9.12(d，J＝9.2Hz，1H)，10.28(s，1H).
Embodiment 44: compd A-84 synthetic
(162mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 3-methoxybenzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-84 (40mg, 32%), fusing point: 205～208 ℃.
HRMS-ESI(M/Z)：484.14417【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.4Hz，2H)，3.90(s，3H)，4.07(s，3H)，5.23(t，J＝6.4Hz，2H)，6.41(s，2H)，7.74-7.79(m，1H)，7.60-7.65(m，2H)，7.76(s，1H)，7.89(d，J＝7.6Hz，1H)8.26(d，J＝9.2Hz，1H)，8.44(d，J＝9.6Hz，1H)，8.96(d，J＝9.2Hz，1H)，9.14(d，J＝9.2Hz，1H)，10.23(s，1H).
Embodiment 45: compd A-85 synthetic
(146mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with the 3-fluorobenzoic acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-85 (46mg, 38%), fusing point: 198～201 ℃.
HRMS-ESI(M/Z)：468.12509【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.4Hz，2H)，4.06(s，3H)，5.23(t，J＝6.4Hz，2H)，6.39(s，2H)，7.59(s，1H)，7.75-7.79(m，2H)，8.09(d，J＝9.2Hz，1H)，8.14-8.19(m，2H)，8.40(d，J＝9.2Hz，1H)，8.87(d，J＝9.2Hz，1H)，9.07(d，J＝9.6Hz，1H)，10.27(s，1H).
Embodiment 46: compd A-86 synthetic
(162mg 1.04mmol) is added in the thionyl chloride (5ml), refluxes 2 hours, and unnecessary solvent thionyl chloride is removed in underpressure distillation with O-Anisic Acid.(99mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes, and (84 μ l 1.04mmol), add above-mentioned acyl chlorides then, continue to reflux 6 hours, and the flaggy monitoring reaction is complete to add anhydrous pyridine with A-30.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains red product A-86 (30mg, 24%), fusing point: 183～185 ℃.
HRMS-ESI(M/Z)：484.14358【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.61(t，J＝6.4Hz，2H)，3.93(s，3H)，4.08(s，3H)，5.24(t，J＝6.4Hz，2H)，6.40(s，2H)，7.18-7.22(m，1H)，7.33-7.35(m，1H)，7.59(s，1H)，7.75-7.79(m，1H)，8.21-8.26(m，2H)，8.43(d，J＝9.2Hz，1H)，8.95(d，J＝9.2Hz，1H)，9.10(d，J＝9.2Hz，1H)，10.12(s，1H).
Embodiment 47: compd A-87 synthetic
With A-30 (99mg 0.26mmol) is dissolved in DMF (5ml), add then porphyrize Pottasium Hydroxide (30mg, 0.52mmol) with 4-nitrobenzyl chlorine (134 μ l; 1.04mmol), being heated to 60 ℃ of reactions 12 hours, concentrating under reduced pressure removes and desolvates, and resistates is transferred PH to 3 with Hydrogen chloride; Suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column; Obtain orange product A-87 (72mg, 57%), fusing point: 208～210 ℃.
HRMS-ESI(M/Z)：481.13863【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.62(t，J＝6.4Hz，2H)，4.11(s，3H)，5.24(t，J＝6.4Hz，2H)，5.57(s，2H)，6.40(s，2H)，7.60(s，1H)，7.92(d，J＝8.4Hz，2H)，8.22(d，J＝9.2Hz，1H)，8.30(d，J＝8.8Hz，2H)，8.34(d，J＝9.2Hz，1H)，8.88-8.91(m，2H)，10.10(s，1H).
Embodiment 48: compd A-36 synthetic
Under 90 ℃ with Phloroglucinol (3.0g, 18.5mmol) repeatedly be added in batches 60% sulfuric acid (60ml, v/v) in until forming colorless cleared solution; Add A (3.0g then in batches; 7.6mmol) form the scarlet suspension, add the insulation of material back and continue reaction 10 hours, the flaggy monitoring reaction is complete.Under the vigorous stirring, reacting liquor while hot is inclined to saturated aqueous common salt (50ml), stirring at room 2 hours is put into negative 20 ℃ of refrigerators then and is fully cooled off.Suction filtration, solid is used distilled water wash, and it is dissolved in 1NNaOH (100ml); Use 2N HCl (100ml) that the system furnishing is acid subsequently, fully stir, suction filtration is collected the solid of separating out; With the methylene chloride is moving phase, and with the separation and purification of decompression silicagel column, the gained solid is used ethanol again: concentrated hydrochloric acid (V: V=95: 5) system recrystallization; Obtain red product A-36 (1.8g, 62%), fusing point: 225～227 ℃.
HRMS-ESI(M/Z)：348.1240【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.54(t，J＝6.4Hz，2H)，4.11(s，3H)，4.15(s，3H)，5.21(t，J＝6.4Hz，2H)，7.34(s，1H)，8.28(d，J＝9.2Hz，1H)，8.48(d，J＝9.2Hz，1H)，8.77(d，J＝9.6Hz，1H)，8.82(d，J＝9.2Hz，1H)，9.61(s，1H)，10.07(s，1H)，10.36(s，1H).
Embodiment 49: compd A-60 synthetic
(100mg 0.26mmol) is suspended in the dry acetonitrile (5ml), is warming up to the basic dissolving that refluxes with A-36; (84 μ l 1.04mmol), add fluorobenzoyl chloride (185 μ l then to add anhydrous pyridine; 1.56mmol), continuing to reflux 6 hours, the flaggy monitoring reaction is complete.Fully cooling, suction filtration is collected the solid of separating out, and is moving phase with the methylene chloride, with the separation and purification of decompression silicagel column, obtains yellow product A-60 (18mg, 11%), fusing point: 169～171 ℃.
HRMS-ESI(M/Z)：592.1569【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.80(t，J＝6.4Hz，2H)，4.14(s，3H)，4.20(s，3H)，5.38(t，J＝6.4Hz，2H)，7.34-7.44(m，4H)，8.03(s，1H)，8.07(dd，J＝5.6，8.8Hz，2H)，8.23(dd，J＝5.2，8.8Hz，2H)，8.37(d，J＝9.2Hz，1H)，8.48(d，J＝9.6Hz，1H)，8.96(d，J＝9.6Hz，1H)，9.08(d，J＝9.6Hz，1H)，10.31(s，1H).
Embodiment 50: compd A-65 synthetic
To be dissolved with Peng Qinghuana (1.2g, 5% sodium hydroxide solution (10ml) 32mmol) dropwise be added to contain Fibrauretin (7.8g, 20mmol) and salt of wormwood (8.3g; In methyl alcohol 60mmol) (250ml) solution system; Stirring at room 2 hours, suction filtration is collected the yellow-green colour solid of separating out, and filter cake is used zero(ppm) water (100ml) and 80% ethanol (100ml) washing successively; Obtain midbody dihydro Fibrauretin (4.4g, 62%).(4.2g 12mmol) is dissolved in the acetonitrile (160ml), adds the oxalic dialdehyde (2ml) of acetate (40ml) and 40% then, is heated to 85～95 ℃ and refluxes 5 hours with midbody dihydro Fibrauretin; The flaggy monitoring reaction is complete, and reaction solution is concentrated, and obtains scarlet oily matter, adds 2% hydrochloric acid soln (200ml); Stirring at room 1 hour is filtered, filtrating stirring at room 5 days; Reaction solution is concentrated, use 95% ethyl alcohol recrystallization, products therefrom washs with ether; Get yellow product A-65 (2.9g, 59%), fusing point: 105～107 ℃.
HRMS-ESI(M/Z)：376.1564【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.67(t，J＝6.8Hz，2H)，3.97(s，3H)，4.06(s，3H)，4.12(s，3H)，4.17(s，3H)，5.27(t，J＝6.8Hz，2H)，7.72(s，1H)，8.32(d，J＝9.2Hz，1H)，8.45(d，J＝9.2Hz，1H)，8.88(d，J＝9.2Hz，1H)，8.92(d，J＝9.6Hz，1H)，10.15(s，1H).
Embodiment 51: compd A-66 synthetic
(2.0g 4.9mmol) places the 250ml round-bottomed flask, and maintenance vacuum tightness is 30～40mmHg, is heated to 195～210 ℃ of reactions 30 minutes, and the solid color is deepened gradually, all becomes scarlet at last with A-65.With the methylene chloride is moving phase, and with the separation and purification of decompression silicagel column, ethanol: (V: V=95: 5) the system acidifying obtains red product A-66 (1.5g, 77%), fusing point: 110～112 ℃ to concentrated hydrochloric acid.
HRMS-ESI(M/Z)：362.1395【M-Cl】
+
1H?NMR(CD
3SOCD
3，400MHz)：δ3.56(t，J＝6.4Hz，2H)，3.94(s，3H)，3.95(s，3H)，4.02(s，3H)，5.02(t，J＝6.4Hz，2H)，7.61(s，1H)，7.79(d，J＝8.0Hz，1H)，7.92(s，1H)，8.27(d，J＝9.2Hz，1H)，8.66(d，J＝9.2Hz，1H)，9.74(s，1H).
Test Example 1: the The compounds of this invention antiproliferative activity is measured
Material and method
1, receive the reagent thing: the compound of certain exemplary of the present invention, contrast medicine be NSC 107124 (10-hydroxycamptothecin, HCPT).
2, cell strain: HepG2 cell.
3, liquor strength is 0.6 μ g/mL.
4, method: be inoculated in 96 well culture plates behind the HepG2 cell dissociation counting with logarithmic phase, 5000/hole/200 μ L, dosing behind the 24h, every group of medicine established 5 multiple holes, and establishes DMSO solvent control wells and acellular zeroing hole.In 37 ℃, 5%CO
2Cultivate 48h under the condition, every hole, PBS washing back adds 200 μ L PBS again, and trichoroacetic acid(TCA) (TCA) fixed cell of Dropwise 50 μ L 50% (m/v), TCA final concentration are 10%, 4 ℃ and placed 1 hour.Abandon stationary liquid, with distilled water wash 5 times, seasoning in the air.Every hole adds the sulphonyl rhodamine solution of 50 μ L, room temperature held 10-30min.Remove supernatant, the acetic acid washing with 1% 5 times, dry air.Add Tris solution (pH=10.5) the 150 μ L of 10mmol/l at last, 5min vibrates on oscillator plate.(Model3550 Bio-Rad) measures the OD value, and with the blank zeroing, used wavelength is 570nm at enzyme-linked immunosorbent assay instrument.Calculate the inhibiting rate of growth of tumour cell by following formula:
Inhibiting rate=[(OD
570 control wells-OD
570 dosing holes)/OD
570 control wells] * 100%.
More than test triplicate, obtain average inhibiting rate.
Under the same measured condition, the inhibiting rate of contrast medicine HCPT is 85.4%.The result shows that The compounds of this invention has positive effect aspect antiproliferative.
Test Example 2: with MCF-7, Hela, HT1080 and four kinds of tumour cell SCREENED COMPOUND of HCT116
Material and method
1, receive the reagent thing: the compound of certain exemplary of the present invention, contrast medicine be NSC 107124 (10-hydroxycamptothecin, HCPT).
2, cell strain: MCF-7, Hela, HT1080 and HCT116.
3, liquor strength is 0.6 μ g/mL.
4, method: be inoculated in 96 well culture plates behind the cell dissociation counting with logarithmic phase, 5000/hole/200 μ L, dosing behind the 24h, every group of medicine established 5 multiple holes, and establishes DMSO solvent control wells and acellular zeroing hole.Under 37 ℃, 5%CO2 condition, cultivate 48h, every hole, PBS washing back adds 200 μ L PBS again, and trichoroacetic acid(TCA) (TCA) fixed cell of Dropwise 50 μ L 50% (m/v), TCA final concentration are 10%, 4 ℃ and placed 1 hour.Abandon stationary liquid, with distilled water wash 5 times, seasoning in the air.Every hole adds the sulphonyl rhodamine solution of 50 μ L, room temperature held 10-30min.Remove supernatant, the acetic acid washing with 1% 5 times, dry air.Add Tris solution (pH=10.5) the 150 μ L of 10mmol/l at last, 5min vibrates on oscillator plate.(Model3550 Bio-Rad) measures the OD value, and with the blank zeroing, used wavelength is 570nm at enzyme-linked immunosorbent assay instrument.Calculate the inhibiting rate of growth of tumour cell by following formula:
Inhibiting rate=[(OD570 control wells-OD570 dosing holes)/OD570 control wells] * 100%.
More than test triplicate, obtain average inhibiting rate.Part of compounds of the present invention sees the following form to the activity of tumor cell proliferation:
The result shows that under the same measured condition, The compounds of this invention has positive effect aspect antiproliferative.
Test Example 3: the IC of compd A-35, A-55, A-40 and A-56 pair cell HepG2 and HCT116
50Measure
Material and method
1, receives the reagent thing: the compound of certain exemplary of the present invention.
2, cell strain: HepG2 and HCT116.
3, liquor strength is 2 μ g/mL, 1 μ g/mL, 0.5 μ g/mL, 0.25 μ g/mL and 0.125 μ g/mL.
4, method: be inoculated in 96 well culture plates behind the cell dissociation counting with logarithmic phase, 5000/hole/200 μ L, dosing behind the 24h, every group of medicine established 5 multiple holes, and establishes DMSO solvent control wells and acellular zeroing hole.Under 37 ℃, 5%CO2 condition, cultivate 48h, every hole, PBS washing back adds 200 μ L PBS again, and trichoroacetic acid(TCA) (TCA) fixed cell of Dropwise 50 μ L 50% (m/v), TCA final concentration are 10%, 4 ℃ and placed 1 hour.Abandon stationary liquid, with distilled water wash 5 times, seasoning in the air.Every hole adds the sulphonyl rhodamine solution of 50 μ L, room temperature held 10-30min.Remove supernatant, the acetic acid washing with 1% 5 times, dry air.Add Tris solution (pH=10.5) the 150 μ L of 10mmol/l at last, 5min vibrates on oscillator plate.(Model3550 Bio-Rad) measures the OD value, and with the blank zeroing, used wavelength is 570nm at enzyme-linked immunosorbent assay instrument.Calculate the inhibiting rate of growth of tumour cell by following formula:
IC50 adopts the IC among the sigmaplot
50Calculation formula obtains.
More than test triplicate, obtain IC
50Part of compounds of the present invention is to the IC of tumour cell
50Be listed in the table below:
The IC of The compounds of this invention
50All lower, numerical value all below 1 μ M, has positive effect aspect antiproliferative.
Test Example 4: compd A-35 couple mdr cell IC
50Mensuration
Material and method
1, receives the reagent thing: compd A of the present invention-35 and Zorubicin.
The cell strain MCF-7/DOX of 2, cell strain: MCF-7 and adriamycin-resistant.
3, liquor strength is 0.5 μ g/mL, 1 μ g/mL, 2 μ g/mL, 4 μ g/mL, 8 μ g/Ml, 16 μ g/mL, 32 μ g/mL and 64 μ g/mL.
4, method: be inoculated in 96 well culture plates behind the cell dissociation counting with logarithmic phase, 5000/hole/200 μ L, dosing behind the 24h, every group of medicine established 5 multiple holes, and establishes DMSO solvent control wells and acellular zeroing hole.Under 37 ℃, 5%CO2 condition, cultivate 48h, every hole, PBS washing back adds 200 μ L PBS again, and trichoroacetic acid(TCA) (TCA) fixed cell of Dropwise 50 μ L 50% (m/v), TCA final concentration are 10%, 4 ℃ and placed 1 hour.Abandon stationary liquid, with distilled water wash 5 times, seasoning in the air.Every hole adds the sulphonyl rhodamine solution of 50 μ L, room temperature held 10-30min.Remove supernatant, the acetic acid washing with 1% 5 times, dry air.Add Tris solution (pH=10.5) the 150 μ L of 10mmol/l at last, 5min vibrates on oscillator plate.(Model3550 Bio-Rad) measures the OD value, and with the blank zeroing, used wavelength is 570nm at enzyme-linked immunosorbent assay instrument.Calculate the inhibiting rate of growth of tumour cell by following formula:
IC50 adopts the IC among the sigmaplot
50Calculation formula obtains.
More than test triplicate, obtain IC
50The result sees Fig. 1.
Visible by the result, The compounds of this invention can reverse the resistance of the cell of adriamycin-resistant.
Test Example 5: cell cycle analysis
Material and method
1, receives the reagent thing: compd A of the present invention-35.
2, cell strain: HCT116 cell.
3, liquor strength is 0.5 μ g/mL.
4, method: handle the HCT116 cell with 0.5 μ g/mL, the cell after 4h, 12h and 24h collect drug-treated respectively, PBS washes twice; 75% ethanol that adds precooling ,-20 ℃ of fixed overnight, the centrifugal ethanol of removing; PBS washes twice, adds the 200mgmL-1RNA enzyme, 37 ℃ of digestion 30min; Add iodate pyridine 25mgmL-1,4 ℃ of lucifuges.
The result sees Fig. 2.The result shows that The compounds of this invention is arrested in the G2/M phase with cell.
Test Example 6: topoisomerase experiment
Material and method
1, receives the reagent thing: compd A of the present invention-35.
2, experimental subjects: topoisomerase I with and substrate pBR322DNA.
3, liquor strength is 30 μ g/mL, 3 μ g/mL and 0.3 μ g/mL.
4, method: topoisomerase I is active to be determined in the reaction system of 20 μ l and to contain 10 * reaction buffer (350mmol/L Tris-HCl pH8.0mmol/L, 720mmol/L Repone K, 5mmol/L magnesium chloride; 50mmol/L DTT; 50mmol/L Spermidine) 2 μ l, 0.1%BAS 2 μ l, PBR3220.36 μ g; Positive control pipe (NSC 107124) final concentration is 212.5 μ g/ml, 10.6 μ g/ml.Each test tube adds the A-35 (final concentration is respectively 30 μ g/mL, 3 μ g/mL and 0.3 μ g/mL) of different concns respectively.Topoisomerase I, each effective zero(ppm) water is supplemented to 20 μ l, and the rearmounted 37 ℃ of reaction 30min of mixing add 5 μ l stop buffers (5% SDD, 40% sucrose, 0.25mg/ml bromjophenol blue) termination reaction.In the TBE electrophoretic buffer, carry out agarose electrophoresis, under the 40V voltage, electrophoresis 4h.Bromination second pyridine solution (1 μ g/ μ l) dyeing 30min puts the Zone electophoresis band of observing DNA under the 260nm ultraviolet ray, and takes the photograph the sheet record.
The result sees Fig. 3.The result shows that The compounds of this invention is inhibited to topoisomerase I.
Claims (10)
1. formula I compound:
Or its pharmacologically acceptable salts or solvate, wherein
X is a halogen;
R
1Be selected from: hydrogen, C
1-6Alkyl, the substituted C of phenyl
1-6Alkyl, C
1-18Alkyl acyl, benzoyl-, benzenesulfonyl, 3,4-C
1-3The alkylenedioxy group benzoyl-, wherein said phenyl is optional to be selected from following substituting group replacement by 1 to 4: halogen, C
1-6Alkyl, C
1-6Alkoxyl group, nitro, cyanic acid, amino, hydroxyl, C
1-4Alkyl acyl is amino;
R
2And R
3Be selected from independently of one another: hydrogen, C
1-6Alkyl, benzoyl-, wherein said phenyl is optional to be replaced by 1 to 4 halogen; Perhaps R
2And R
3Be together-CH
2-.
2. the compound of claim 1, wherein X is selected from fluorine, chlorine, bromine, iodine.
3. each compound of claim 1 to 2, wherein R is selected from hydrogen, C
1-4Alkyl, the substituted C of phenyl
1-4Alkyl, C
1-16Alkyl acyl, benzoyl-, benzenesulfonyl, 3,4-C
1-2The alkylenedioxy group benzoyl-, wherein said phenyl is optional to be selected from following substituting group replacement by 1 to 4: halogen, C
1-4Alkyl, C
1-4Alkoxyl group, nitro, cyanic acid, amino, hydroxyl, C
1-4Alkyl acyl is amino.
4. each compound of claim 1 to 3, wherein R
2And R
3Be selected from independently of one another: hydrogen, C
1-4Alkyl, halogeno-benzene formyl radical; Perhaps R
2And R
3Be together-CH
2-.
5. each compound of claim 1 to 4, it is a following formula: compound,
R wherein
1, R
2, R
3Have following each said implication of numbering No1 to No51 with X:
6. each compound of claim 1 to 5, it is to be selected from following compound:
9,10-dimethoxy-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-hydroxyl-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-oxyethyl group-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-bromide;
9-butoxy-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-iodide;
9-benzyloxy-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-bromide;
9-(2,4 difluorobenzene base) methoxyl group-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-bromide;
9-ethanoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-benzoyl-Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to methyl benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to anisoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to fluoro benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to fluorine m-nitro benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to methyl m-nitro benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to methoxyl group m-nitro benzoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-(3,4-methylene-dioxy benzoyl-oxygen base)-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-(3,4,5-trimethoxy benzoyl-oxygen base)-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
The adjacent fluoro benzoyl Oxy-1 of 9-0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
The adjacent chlorobenzene formacyl Oxy-1 of 9-0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-(2,4 difluorobenzene formyl radical oxygen base)-10-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-is to acetamido benzenesulfonyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole and 4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-benzenesulfonyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquinoline 99.9 [8,1,2-cde] phenanthridines-7-muriate;
9-decanoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-lauroyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
9-hexadecanoyl Oxy-1 0-methoxyl group-5,6-dihydro-[1,3] dioxole also [4 ', 5 ': 6,7] isoquino [8,1,2-cde] phenanthridines-7-muriate;
Or its pharmacologically acceptable salts or solvate.
7. prepare the method for each said compound of claim 1 to 6, it may further comprise the steps:
A) in solvent, in the presence of alkali, make the reaction of Peng Qinghuana and Berberine, obtain dihydroberberine;
B) in solvent, in the presence of acid, make dihydroberberine and glyoxal reaction, obtain the cyclisation Berberine shown in the formula Ia:
Choose wantonly, c) make formula Ia cyclisation Berberine under vacuum, at high temperature handle and to obtain the 9-hydroxyl cyclisation Berberine shown in the formula Ib:
Choose wantonly, d) in organic solvent, in the presence of alkali, make 9-hydroxyl cyclisation Berberine and the suitable reagent reaction of formula Ib, obtain 9-alkyl oxy cyclisation Berberine, alkyl wherein is optional to be replaced by phenyl or substituted phenyl;
Choose wantonly; E) in organic solvent, in the presence of reagent, make 9-hydroxyl cyclisation Berberine and acyl chlorides or the SULPHURYL CHLORIDE reaction of formula Ib; Obtain 9-acyloxy cyclisation Berberine or 9-alkylsulfonyl oxygen basic ring Berberine, acyl group wherein is alkyloyl or benzoyl-.
8. pharmaceutical composition, it comprises each said compound of claim 1 to 6, and optional one or more pharmaceutically acceptable carriers or vehicle.
9. each said compound of claim 1 to 6 is used for treating and/or preventing the purposes of the medicine of mammal tumor or cancer property disease in preparation.
10. the purposes of claim 9, wherein said tumour or cancer property disease are liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210101607.XA CN102746292B (en) | 2011-04-18 | 2012-04-09 | Cyclized berberine derivatives, preparation method and uses thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110096343 | 2011-04-18 | ||
| CN201110096343.9 | 2011-04-18 | ||
| CN2011100963439 | 2011-04-18 | ||
| CN201210101607.XA CN102746292B (en) | 2011-04-18 | 2012-04-09 | Cyclized berberine derivatives, preparation method and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102746292A true CN102746292A (en) | 2012-10-24 |
| CN102746292B CN102746292B (en) | 2015-03-18 |
Family
ID=47026840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210101607.XA Expired - Fee Related CN102746292B (en) | 2011-04-18 | 2012-04-09 | Cyclized berberine derivatives, preparation method and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102746292B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188035A (en) * | 2016-06-30 | 2016-12-07 | 合肥华方医药科技有限公司 | The Preparation method and use of 9 substituted double-functional group berberinc derivates |
| CN107722000A (en) * | 2017-11-03 | 2018-02-23 | 中国药科大学 | The preparation of the berberinc derivate of 9-substitution and its medical usage |
| WO2018068769A1 (en) * | 2016-10-14 | 2018-04-19 | 中国医学科学院药物研究所 | Use of dihydroberberine type compounds in preparation of product for treating tumour diseases associated with stat3 signaling pathway |
| CN108822095A (en) * | 2018-07-25 | 2018-11-16 | 山东大学 | Benzo [h] chromene compound and its application as AcrB efflux pump inhibitor in antibacterial |
| CN109928967A (en) * | 2017-11-28 | 2019-06-25 | 中国医学科学院医药生物技术研究所 | A kind of cyclisation berberinc derivate and its preparation method and application |
| CN114736202A (en) * | 2022-04-20 | 2022-07-12 | 四川大学 | Preparation and application of berberine derivative with IDO1/TDO inhibitory activity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1211252A (en) * | 1996-02-12 | 1999-03-17 | 新泽西州州立大学(拉特格斯) | Coralyne analogs as topoisomerase inhibitors |
| CN101255158A (en) * | 2008-03-28 | 2008-09-03 | 中山大学 | 9-N-substituted berberine derivatives as well as preparation method and use as anti-cancer drugs |
| US20110015222A1 (en) * | 2009-07-20 | 2011-01-20 | Naxospharma S.R.L. | Benzoquinolizinium salt derivatives as anticancer agents |
-
2012
- 2012-04-09 CN CN201210101607.XA patent/CN102746292B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1211252A (en) * | 1996-02-12 | 1999-03-17 | 新泽西州州立大学(拉特格斯) | Coralyne analogs as topoisomerase inhibitors |
| CN101255158A (en) * | 2008-03-28 | 2008-09-03 | 中山大学 | 9-N-substituted berberine derivatives as well as preparation method and use as anti-cancer drugs |
| US20110015222A1 (en) * | 2009-07-20 | 2011-01-20 | Naxospharma S.R.L. | Benzoquinolizinium salt derivatives as anticancer agents |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188035A (en) * | 2016-06-30 | 2016-12-07 | 合肥华方医药科技有限公司 | The Preparation method and use of 9 substituted double-functional group berberinc derivates |
| WO2018068769A1 (en) * | 2016-10-14 | 2018-04-19 | 中国医学科学院药物研究所 | Use of dihydroberberine type compounds in preparation of product for treating tumour diseases associated with stat3 signaling pathway |
| CN107722000A (en) * | 2017-11-03 | 2018-02-23 | 中国药科大学 | The preparation of the berberinc derivate of 9-substitution and its medical usage |
| CN109928967A (en) * | 2017-11-28 | 2019-06-25 | 中国医学科学院医药生物技术研究所 | A kind of cyclisation berberinc derivate and its preparation method and application |
| CN109928967B (en) * | 2017-11-28 | 2020-09-04 | 中国医学科学院医药生物技术研究所 | Cyclized berberine derivative and preparation method and application thereof |
| CN108822095A (en) * | 2018-07-25 | 2018-11-16 | 山东大学 | Benzo [h] chromene compound and its application as AcrB efflux pump inhibitor in antibacterial |
| CN108822095B (en) * | 2018-07-25 | 2020-05-01 | 山东大学 | Benzo [ h ] chromene compound and application thereof as AcrB efflux pump inhibitor in antibiosis |
| CN114736202A (en) * | 2022-04-20 | 2022-07-12 | 四川大学 | Preparation and application of berberine derivative with IDO1/TDO inhibitory activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102746292B (en) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2970145B1 (en) | Compounds and compositions for the treatment of cancer | |
| CN102746292B (en) | Cyclized berberine derivatives, preparation method and uses thereof | |
| JP7030093B2 (en) | How to make an oxathiadin-like compound | |
| CN101268048A (en) | Carbazole derivatives | |
| WO1997037989A1 (en) | Indole derivatives as 5-ht receptor antagonist | |
| BRPI0715745A2 (en) | compounds and methods for inhibiting bcl protein interaction with ligand partners | |
| WO2016155545A1 (en) | Sulfamyl-containing 1,2,5-oxadiazole derivative, preparation method therefor and use thereof in pharmaceuticals | |
| CN102731485A (en) | 4-(substituted phenylamino)quinazoline derivative, its preparation method, pharmaceutical composition and application | |
| CN102485721A (en) | Substituted 2,3-phthalazinone compounds and application thereof | |
| CN101374807B (en) | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | |
| CN102746291B (en) | 13-substituted berberine derivatives and preparation method thereof, and uses of 13-substituted berberine derivatives as anti-tuberculosis drugs | |
| CN101503394B (en) | High piperazine acetydrazide derivatives, and preparation and use thereof | |
| CN101565409B (en) | Piperazidine or homopiperazine oxalyl hydrazine class compound, preparation and use thereof | |
| BRPI0712483A2 (en) | 6-Methoxy-8- [4-1- (5-fluoro) -quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline hydrochloric acid salts | |
| GB2243832A (en) | 2-substituted 4-acetamido-5-chloro-n-[2-(diethylamino)ethyl]-benzamide derivative | |
| CN103319402B (en) | Diphenyl thiourea derivatives, preparation method and applications thereof | |
| CN102653522B (en) | Diphenyl thiourea compounds of ω-carboxyl substituted and its production and use | |
| US11479528B2 (en) | Heat shock protein 90 inhibitors | |
| BRPI0713107A2 (en) | 6-Methoxy-8- [4- (1- (5-fluoro) -quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline siccinate salts, and crystalline forms thereof | |
| JPH01294670A (en) | 2-(piperadinyl)-2-oxoethylene-substituted flavonoid derivative, its production and pharmaceutical composition containing said derivative | |
| CN101941953B (en) | Nitrogenous heterocyclic substituted hydrazide compounds as well as preparation methods and applications thereof | |
| EP3253749B1 (en) | Compounds with anti-tumoral activity | |
| CN101987835A (en) | Homopiperazine acethydrazide derivatives | |
| US6174918B1 (en) | Naphthoquinone antitumor compound and method | |
| CN102838567B (en) | Benzenesulfonyl piperazine compounds or benzoyl piperazine compounds, preparation methods and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150318 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |